{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:48:18Z","timestamp":1793137698170,"version":"4.5.0"},"reference-count":734,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T00:00:00Z","timestamp":1564444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicines"],"abstract":"<jats:p>Prostate cancer is the most frequent nonskin cancer and second most common cause of cancer-related deaths in man. Prostate cancer is a clinically heterogeneous disease with many patients exhibiting an aggressive disease with progression, metastasis, and other patients showing an indolent disease with low tendency to progression. Three stages of development of human prostate tumors have been identified: intraepithelial neoplasia, adenocarcinoma androgen-dependent, and adenocarcinoma androgen-independent or castration-resistant. Advances in molecular technologies have provided a very rapid progress in our understanding of the genomic events responsible for the initial development and progression of prostate cancer. These studies have shown that prostate cancer genome displays a relatively low mutation rate compared with other cancers and few chromosomal loss or gains. The ensemble of these molecular studies has led to suggest the existence of two main molecular groups of prostate cancers: one characterized by the presence of ERG rearrangements (~50% of prostate cancers harbor recurrent gene fusions involving ETS transcription factors, fusing the 5\u2032 untranslated region of the androgen-regulated gene TMPRSS2 to nearly the coding sequence of the ETS family transcription factor ERG) and features of chemoplexy (complex gene rearrangements developing from a coordinated and simultaneous molecular event), and a second one characterized by the absence of ERG rearrangements and by the frequent mutations in the E3 ubiquitin ligase adapter SPOP and\/or deletion of CDH1, a chromatin remodeling factor, and interchromosomal rearrangements and SPOP mutations are early events during prostate cancer development. During disease progression, genomic and epigenomic abnormalities accrued and converged on prostate cancer pathways, leading to a highly heterogeneous transcriptomic landscape, characterized by a hyperactive androgen receptor signaling axis.<\/jats:p>","DOI":"10.3390\/medicines6030082","type":"journal-article","created":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T11:15:56Z","timestamp":1564485356000},"page":"82","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":124,"title":["Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications"],"prefix":"10.3390","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7900-8942","authenticated-orcid":false,"given":"Ugo","family":"Testa","sequence":"first","affiliation":[{"name":"Department of Oncology, Istituto Superiore di Sanit\u00e0, Vaile Regina Elena 299, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germana","family":"Castelli","sequence":"additional","affiliation":[{"name":"Department of Oncology, Istituto Superiore di Sanit\u00e0, Vaile Regina Elena 299, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Pelosi","sequence":"additional","affiliation":[{"name":"Department of Oncology, Istituto Superiore di Sanit\u00e0, Vaile Regina Elena 299, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,7,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/978-3-642-81095-4_6","article-title":"Prognosis of prostatic carcinoma","volume":"60","author":"Mellinger","year":"1977","journal-title":"Recent Results Cancer Res."},{"key":"ref_2","first-page":"129","article-title":"Survival rates of patients with prostatic cancer, tumor stage, and differentiation-preliminary report","volume":"50","author":"Bailar","year":"1966","journal-title":"Cancer Chemother. Rep."},{"key":"ref_3","unstructured":"Tannenbaum, M. (1977). Histological grading and staging of prostatic carcinoma. Urologic Pathology: The Prostate, Lea and Feibiger."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/modpathol.2017.133","article-title":"Prostate cancer grading: A decade after the 2005 modified system","volume":"31","author":"Epstein","year":"2018","journal-title":"Modern Pathol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.eururo.2015.06.046","article-title":"A contemporary prostate cancer grading system: A validated alternative to the Gleason score","volume":"69","author":"Epstein","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.eururo.2015.10.040","article-title":"Genomic correlates to the newly proposed grading prognostic groups for prostate cancer","volume":"69","author":"Rubin","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/path.5045","article-title":"Is high-grade prostatic intraepithelial neoplasia (HGPIN) a reliable precursor for prostate carcinoma? Implications for clonal evolution and early detection strategies","volume":"244","author":"Tolkach","year":"2018","journal-title":"J. Pathol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1158\/0008-5472.CAN-12-2799","article-title":"Clonal progression of prostate cancers from Gleason grade 3 to grade 4","volume":"73","author":"Sowalsky","year":"2013","journal-title":"Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1158\/0008-5472.CAN-12-2803","article-title":"Lineage relationship of Gleason patterns in Gleason score 7 prostate cancer","volume":"73","author":"Kovtun","year":"2013","journal-title":"Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/modpathol.2016.63","article-title":"PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: Implications for active surveillance","volume":"29","author":"Trock","year":"2016","journal-title":"Mod. Pathol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/pros.23176","article-title":"Concurrent TMPRSS2-ERG and SLC45A3-ERG rearrangements plus PTEN loss are not found in low grade prostate cancer and define an aggressive tumor subset","volume":"76","author":"Hernandez","year":"2016","journal-title":"Prostate"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/cas.12460","article-title":"Low-grade prostate cancer diverges early from high grade and metastatic disease","volume":"105","author":"VanderWeel","year":"2014","journal-title":"Cancer Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1158\/1078-0432.CCR-16-2414","article-title":"Gleason score 7 prostate cancer emerge through branched evolution of clonal Gleason pattern 3 and 4","volume":"23","author":"Sowalsky","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/ng.3221","article-title":"Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansion in neoplastic and morphologically normal prostate tissue","volume":"47","author":"Cooper","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/modpathol.2014.81","article-title":"Etiologic field effect: Reappraisal of the field effect concept in cancer predisposition and progression","volume":"28","author":"Lochead","year":"2015","journal-title":"Mod. Pathol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/pros.23212","article-title":"Mutation profiling indicates high grade prostatic intraepithelial neoplasia as distant precursors of adjacent invasive prostatic adenocarcinoma","volume":"76","author":"Gerrin","year":"2016","journal-title":"Prostate"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.eururo.2015.10.031","article-title":"Genetic progression of high grade prostatic intraepithelial neoplasia to prostate cancer","volume":"69","author":"Jung","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/path.4628","article-title":"Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization","volume":"238","author":"Haffner","year":"2016","journal-title":"J. Pathol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Trabzonlu, L., Kulac, I., Zheng, Q., Hicks, J.L., Haffner, M.C., Nelson, W.G., Sfanos, K.S., Ertunc, O., Lotan, T.L., and Heaphy, C.M. (2018). Molecular Pathology of High-Grade Prostatic Intraepithelial Neoplasia: Challenges and Opportunities. Cold Spring Harb. Perspect Med., 9.","DOI":"10.1101\/cshperspect.a030403"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1038\/modpathol.2017.138","article-title":"High-grade prostatic intraepithelial neoplasia, PIN-like carcinoma, ductal carcinoma, and intraductal carcinoma of the prostate","volume":"31","author":"Zhou","year":"2018","journal-title":"Mod. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1097\/PAS.0000000000001139","article-title":"PIN-like (Ductal) Adenocarcinoma of the Prostate","volume":"42","author":"Paulk","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/modpathol.2009.79","article-title":"Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma","volume":"22","author":"Han","year":"2009","journal-title":"Mol. Pathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1002\/pros.23042","article-title":"PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas","volume":"75","author":"Morais","year":"2015","journal-title":"Prostate"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"82504","DOI":"10.18632\/oncotarget.12697","article-title":"Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate","volume":"7","author":"Schweizer","year":"2016","journal-title":"Oncotarget"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/pros.23484","article-title":"Intraductal\/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer","volume":"78","author":"Silberstein","year":"2018","journal-title":"Prostate"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.euf.2017.12.003","article-title":"Integrative Genomic Analysis of Coincident Cancer Foci Implicates CTNNB1 and PTEN Alterations in Ductal Prostate Cancer","volume":"5","author":"Gillard","year":"2019","journal-title":"Eur. Urol. Focus"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2017.04.015","article-title":"Genetic profile of ductal adenocarcinoma of prostate","volume":"69","author":"Seipel","year":"2017","journal-title":"Human Pathol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/path.4186","article-title":"Nucleotide resolution analysis of TMPRSS2 and ERG rearrangements in prostate cancer","volume":"230","author":"Weier","year":"2013","journal-title":"J. Pathol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.eururo.2014.09.006","article-title":"Tracking the origin of metastatic prostate cancer","volume":"67","author":"Lindberg","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"13671","DOI":"10.1038\/ncomms13671","article-title":"Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories","volume":"8","author":"Taylor","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/modpathol.2016.49","article-title":"Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy","volume":"29","author":"Kweldam","year":"2016","journal-title":"Mod. Pathol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Bottcher, R., Kweldam, C.F., Livingstone, J., Lalonde, E., Yamaguchi, T.N., Huang, V., Yousif, F., Fraser, M., Bristow, R.G., and van der Kwast, T. (2018). Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations. BMC Cancer, 8.","DOI":"10.1186\/s12885-017-3976-z"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1158\/1541-7786.MCR-18-0440","article-title":"Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate","volume":"17","author":"Elfandy","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1158\/1078-0432.CCR-16-1454","article-title":"Molecular Profiling to Determine Clonality of Serial Magnetic Resonance Imaging\/Ultrasound Fusion Biopsies from Men on Active Surveillance for Low-Risk Prostate Cancer","volume":"23","author":"Palapattu","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.eururo.2012.03.050","article-title":"Exome sequencing of prostate cancer supports the hypothesis of independent tumor origins","volume":"63","author":"Lindberg","year":"2013","journal-title":"Eur. Urol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/ng.3315","article-title":"Spatial genomic heterogeneity within localized, multifocal prostate cancer","volume":"47","author":"Boutros","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.eururo.2016.07.008","article-title":"Intratumoral and intertumoral genomic heterogeneity of multifocal localized prostate cancer impacts molecular classifications and genomic prognosticators","volume":"71","author":"Wei","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_38","unstructured":"Cancer Atlas Research Network (2015). The molecular taxonomy of primary prostate cancer. Cell, 163, 1011\u20131025."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.euf.2018.01.006","article-title":"Genomic heterogeneity within individual prostate cancer foci impacts predictive biomarkers of targeted therapy","volume":"5","author":"VanderWeele","year":"2019","journal-title":"Eur. Urol. Focus"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e123468","DOI":"10.1172\/jci.insight.123468","article-title":"Transcriptomic heterogeneity in multifocal prostate cancer","volume":"3","author":"Salami","year":"2018","journal-title":"JCI Insight"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1038\/s41467-018-04724-5","article-title":"Spatial maps of prostate cancer trascriptomes reveal an unexplored landscape of heterogeneity","volume":"9","author":"Berglund","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.eururo.2018.06.005","article-title":"Spatial intratumoral genomic heterogeneity within localized prostate cancer revealed by single-nucleus sequencing","volume":"74","author":"Su","year":"2018","journal-title":"Eur. Urol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.eururo.2018.08.009","article-title":"Multifocal primary prostate cancer exhibits high degree of genomic heterogeneity","volume":"75","author":"Lvof","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1101\/gad.1965810","article-title":"Molecular genetics of prostate cancer: New prospects for old challenges","volume":"24","author":"Shen","year":"2010","journal-title":"Genes Dev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nm.1944","article-title":"Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer","volume":"15","author":"Liu","year":"2009","journal-title":"Nat. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4918","DOI":"10.1172\/JCI70354","article-title":"Tracking the clonal origin of lethal prostate cancer origin of lethal prostate cancer","volume":"123","author":"Haffner","year":"2013","journal-title":"J. Clin. Invest."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nature14347","article-title":"The evolutionary history of lethal metastatic prostate cancer","volume":"520","author":"Gundem","year":"2015","journal-title":"Nature"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"6605","DOI":"10.1038\/ncomms7605","article-title":"Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer","volume":"6","author":"Hong","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e124756","DOI":"10.1172\/jci.insight.124756","article-title":"Frequent clonal relations between metastases and non-index prostate cancer lesions","volume":"4","author":"Kneppers","year":"2019","journal-title":"JCI Insight"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"254ra125","DOI":"10.1126\/scitranslmed.3009448","article-title":"Tumor clone dynamics in lethal prostate cancer","volume":"6","author":"Carreira","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"a000752","DOI":"10.1101\/mcs.a000752","article-title":"Integrated clinical, whole-genome, and transcriptome analysis of multisampled lethal metastatic prostate cancer","volume":"2","author":"Bova","year":"2016","journal-title":"Cold Spring Harb. Mol. Case Stud."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature12912","article-title":"Discovery and saturation analysis of cancer genes across 21 tumor types","volume":"505","author":"Lawrence","year":"2014","journal-title":"Nature"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature09744","article-title":"The genomic complexity of primary human prostate cancer","volume":"470","author":"Berger","year":"2011","journal-title":"Nature"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature11125","article-title":"The mutational landscape of lethal castration-resistant prostate cancer","volume":"487","author":"Grasso","year":"2012","journal-title":"Nature"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/ng.2279","article-title":"Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer","volume":"44","author":"Barbieri","year":"2012","journal-title":"Nat. Genet."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1158\/0008-5472.CAN-12-1342","article-title":"CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer","volume":"73","author":"Burkhardt","year":"2013","journal-title":"Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"17087","DOI":"10.1073\/pnas.1108745108","article-title":"Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers","volume":"108","author":"Kumar","year":"2011","journal-title":"Proc. Natl. Acad. Sci USA"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4988","DOI":"10.1038\/ncomms5988","article-title":"Complex MESH2 and MESH6 mutations in hypermutated microsatellite unstable advanced prostate cancer","volume":"5","author":"Pritchard","year":"2014","journal-title":"Nature Commun."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ccr.2013.01.002","article-title":"Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer","volume":"23","author":"Weischenfeldt","year":"2013","journal-title":"Cancer Cell"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.ccell.2018.10.016","article-title":"Molecular evolution of early-onset prostate cancer identifies molecular risk markers and clinical trajectories","volume":"34","author":"Gerhauser","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41588-018-0078-z","article-title":"The long tail of oncogenic drivers in prostate cancer","volume":"50","author":"Armenia","year":"2018","journal-title":"Nat. Genet."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nature20788","article-title":"Genomic hallmarks of localized, non-indolent prostate cancer","volume":"541","author":"Fraser","year":"2017","journal-title":"Nature"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.cell.2018.03.029","article-title":"The evolutionary landscape of localized prostate cancers drives clinical aggression","volume":"173","author":"Espiritu","year":"2018","journal-title":"Cell"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/s41467-017-00377-y","article-title":"Mitochondrial mutations drive prostate cancer aggression","volume":"8","author":"Hopkins","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41588-018-0086-z","article-title":"Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets","volume":"50","author":"Wedge","year":"2018","journal-title":"Nat. Genet."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"12868","DOI":"10.1038\/s41598-018-30325-9","article-title":"Systematic analysis reveals molecular charcteristics of ERG-negative prostate cancer","volume":"8","author":"Xiao","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.cell.2018.06.039","article-title":"Genomic hallmarks and structural variation in metastatic prostate cancer","volume":"174","author":"Quigley","year":"2018","journal-title":"Cell"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/path.4047","article-title":"From sequence to molecular pathology and a mechanism driving the neuroendocrine phenotype in prostate cancer","volume":"227","author":"Lapuk","year":"2012","journal-title":"J. Pathol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/gcc.21999","article-title":"Poly-gene fusion transcripts and chromotripsis in prostate cancer","volume":"51","author":"Wu","year":"2012","journal-title":"Gene Chromosomes Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/path.5052","article-title":"Delineation of human prostate cancer evolution identifies chromotripsis as a polyclonal event and FKBP4 as a potential driver of castration resistance","volume":"245","author":"Quintavalle","year":"2018","journal-title":"J. Pathol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.cell.2013.03.021","article-title":"Punctuated evolution of prostate cancer genomes","volume":"153","author":"Baca","year":"2013","journal-title":"Cell"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nm.4053","article-title":"Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer","volume":"22","author":"Kumar","year":"2016","journal-title":"Nat. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/path.4380","article-title":"Regional biases in mutation screening due to intratumor heterogeneity of prostate cancer","volume":"233","author":"Kim","year":"2014","journal-title":"J. Pathol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1126\/science.aat7171","article-title":"Minimal functional driver gene heterogeneity among untreated metastases","volume":"361","author":"Reiter","year":"2018","journal-title":"Science"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1158\/1078-0432.CCR-18-2068","article-title":"RB1 heterogeneity in advanced metastatic castration-resistant prostate cancer","volume":"25","author":"Casiraghi","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"5433","DOI":"10.1158\/1078-0432.CCR-18-1229","article-title":"The proteome of prostate cancer bone metastasis reveals heterogeneity with prognostic implications","volume":"24","author":"Thysell","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.cancergen.2014.09.003","article-title":"Recurrent copy number alterations in prostate cancer: An in silico meta-analysis of publicly available genomic data","volume":"207","author":"Williams","year":"2014","journal-title":"Cancer Genet."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","article-title":"Integrative genomic profiling of human prostate cancer","volume":"18","author":"Taylor","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1113162","article-title":"Radical prostatectomy versus observation for localized prostate cancer","volume":"367","author":"Wilt","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"11139","DOI":"10.1073\/pnas.1411446111","article-title":"Copy number alteration burden predicts prostate cancer relapse","volume":"111","author":"Hieronymous","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e37294","DOI":"10.7554\/eLife.37294","article-title":"Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death","volume":"7","author":"Hieronymous","year":"2018","journal-title":"eLife"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Camacho, N., Val Loo, P., Edwards, S., Kay, J.D., Matthwes, L., Haase, K., Clark, J., Dennis, N., Thomas, S., and Kremeyer, B. (2017). Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data. PLoS Genet., 13.","DOI":"10.1371\/journal.pgen.1007001"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1073\/pnas.68.4.820","article-title":"Mutation and cancer: Statistical study of retinoblastoma","volume":"68","author":"Knudson","year":"1971","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1126\/science.1219580","article-title":"Recurrent hemizygous deletions in cancers may optimize proliferative potential","volume":"337","author":"Solimini","year":"2012","journal-title":"Science"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.mayocp.2018.06.028","article-title":"Large chromosomal rearrangements yield biomarkers to distinguish low-risk from intermediate- and high-risk prostate cancer","volume":"94","author":"Vasmatzis","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1158\/0008-5472.CAN-11-2724","article-title":"Suppression of TAK1 promotes prostate tumorigenesis","volume":"72","author":"Wu","year":"2013","journal-title":"Cancer Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/modpathol.2012.236","article-title":"Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions","volume":"26","author":"Kluth","year":"2013","journal-title":"Mod. Pathol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"4904","DOI":"10.1158\/1078-0432.CCR-13-1341","article-title":"SPINK1 protein expression and prostate cancer progression","volume":"20","author":"Flavin","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.celrep.2014.06.053","article-title":"Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive prostate cancer","volume":"8","author":"Brocks","year":"2014","journal-title":"Cell Rep."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e386","DOI":"10.1200\/JCO.2011.41.5166","article-title":"Challenges in recognizing treatment-related neuroendocrine prostate cancer","volume":"30","author":"Beltran","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2017.77.6880","article-title":"Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: A multi-istitutional prospective study","volume":"36","author":"Aggarwal","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm.4045","article-title":"Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer","volume":"22","author":"Beltran","year":"2016","journal-title":"Nat. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/iju.13526","article-title":"Clinical and molecular features of treatment-related neuroendocrine prostate cancer","volume":"25","author":"Akamatsu","year":"2018","journal-title":"Int. J. Urol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ccell.2016.09.005","article-title":"N-NYC induces an EZH2-nucleated transcriptional program driving neuroendocrine prostate cancer","volume":"30","author":"Dardenne","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/1078-0432.CCR-18-1912","article-title":"A phase II trial of the Aurora kinase A inhibitor Alistertib for patients with castration resistant and neuroendocrine prostate cancer: Efficacy and biomarkers","volume":"25","author":"Beltran","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1038\/s41467-018-06177-2","article-title":"Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB-EZH2-TSP1 pathway in prostate cancers","volume":"9","author":"Zhang","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41467-018-08133-6","article-title":"ONECUT2 is a driver of neuroendocrine prostate cancer","volume":"10","author":"Guo","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ccell.2019.01.018","article-title":"Increased serine and one-carbon pathway metabolism by PKC\u03bb\/\u03b9 deficiency promotes neuroendocrine prostate cancer","volume":"35","author":"Linares","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1038\/nature07738","article-title":"ETS rearrangements and prostate cancer initiation","volume":"457","author":"Carver","year":"2009","journal-title":"Nature"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1200\/JCO.2013.49.8386","article-title":"TMPRSS2-ERG fusion predicts subsequent detection of prostate cancer patients with high-grade prostatic intraepithelial neoplasia","volume":"32","author":"Park","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1158\/2159-8290.CD-13-1010","article-title":"The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis","volume":"4","author":"Lucas","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00065","article-title":"TMPRSS2-ERG fusions unexpectedly identified in men initially diagnosed with nonprostatic malignancies","volume":"1","author":"Lara","year":"2017","journal-title":"JCO Precis. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1530\/ERC-18-0148","article-title":"Intratumoral androgen levels are linked to TMPRSS2-ERG fusion in prostate cancer","volume":"25","author":"Knuuttila","year":"2018","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.613","article-title":"Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer rearrangements","volume":"42","author":"Haffner","year":"2010","journal-title":"Nat. Genet."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.eururo.2014.06.027","article-title":"TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer","volume":"66","author":"Steurer","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/ng.371","article-title":"Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis","volume":"41","author":"King","year":"2009","journal-title":"Nat. Genet."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/ng.370","article-title":"Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate","volume":"41","author":"Carver","year":"2009","journal-title":"Nat. Genet."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1038\/onc.2014.308","article-title":"TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation","volume":"34","author":"Mounir","year":"2015","journal-title":"Oncogene"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/ng.3419","article-title":"The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis","volume":"47","author":"Pomerantz","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/ng.3930","article-title":"TMPRSS2-ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer","volume":"49","author":"Kron","year":"2017","journal-title":"Nat. Genet."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.molcel.2018.06.040","article-title":"Binding of TMPRS22-ERG to BAF chromatin remodeling complexes mediates prostate oncogenesis","volume":"71","author":"Sandoval","year":"2018","journal-title":"Mol. Cell"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"4551","DOI":"10.1158\/1078-0432.CCR-18-0653","article-title":"TMPRS22-ERG controls luminal epithelial lineage and antiandrogen sensitivity in PTEN and TP53-mutated prostate cancer","volume":"24","author":"Blee","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1158\/0008-5472.CAN-17-2949","article-title":"Identification of a small molecule that selectively inhibits ERG-positive cancer cell growth","volume":"78","author":"Mohamed","year":"2018","journal-title":"Cancer Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1101\/gad.211011.112","article-title":"ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients","volume":"27","author":"Baena","year":"2013","journal-title":"Genes Dev."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nm.3216","article-title":"ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis response to PTEN loss","volume":"19","author":"Chen","year":"2013","journal-title":"Nat. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1038\/modpathol.2014.70","article-title":"Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer","volume":"27","author":"Krohn","year":"2014","journal-title":"Mod. Pathol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.gene.2015.09.068","article-title":"Frequency of PTEN alterations, TMPRSS2-ERG fusion and their association in prostate cancer","volume":"575","author":"Fallahabadi","year":"2016","journal-title":"Gene"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1158\/2159-8290.CD-16-0960","article-title":"Exome sequencing of African-American prostate cancer reveals loss-of-function ERF mutations","volume":"7","author":"Huang","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nature22820","article-title":"ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis","volume":"546","author":"Bose","year":"2017","journal-title":"Nature"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ccr.2009.11.006","article-title":"Steroid hormone receptors in prostate cancer: A hard habit to break?","volume":"16","author":"Attard","year":"2009","journal-title":"Cancer Cell"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.ccell.2017.02.017","article-title":"Development of peptidomimetic inhibitors of the ERG gene fusion product in prostate cancer","volume":"31","author":"Wang","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_123","first-page":"1308","article-title":"Synergistic activity with NOTCH inhibition and androgen ablation in ERG-Positive prostate cancer cells","volume":"15","author":"Mohamed","year":"2017","journal-title":"Mol. Cancer Cell"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Bratsalavsky, G., Fisher, H., Byler, T., Iacob, I., Chung, I., Elvin, I.A., Vergiolio, I.A., Ramkissoon, S., Suh, J., and Allan, E. (2018). Difference of genomic signatures and opportunities for targeted and immunotherapies in castrate resistant TMPRSS2:ERG fusion positive and TPRSS2:ERG wild type refractory acinal (CRPC) and neuroendocrine prostate cancer (CRNEPC). J. Clin. Oncol., 36.","DOI":"10.1200\/JCO.2018.36.6_suppl.348"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"6997","DOI":"10.1073\/pnas.1304502110","article-title":"Prostate cancer associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein","volume":"110","author":"Geng","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"5631","DOI":"10.1158\/0008-5472.CAN-14-0476","article-title":"Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer","volume":"74","author":"Geng","year":"2014","journal-title":"Cancer Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.celrep.2014.01.013","article-title":"Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants","volume":"6","author":"An","year":"2014","journal-title":"Cell Rep."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1038\/onc.2017.80","article-title":"SPOP regulates prostate epithelial cell proliferatrion and promotes ubiquitination and turnover of c-MYC oncoprotein","volume":"36","author":"Geng","year":"2017","journal-title":"Oncogene"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1126\/science.1250255","article-title":"Prostate cancer-ubiquitylone analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer","volume":"346","author":"Theurillat","year":"2014","journal-title":"Science"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"5007","DOI":"10.1038\/s41467-018-07475-5","article-title":"TRIM28 protects TRIM24 from SPOP-mediated degradation and promotes prostate cancer progression","volume":"9","author":"Fong","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.ccell.2016.04.012","article-title":"TRIM24 is an oncogenic transcriptional activator prostate cancer","volume":"29","author":"Groner","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.devcel.2018.11.035","article-title":"SPOP promotes Nanog destruction to suppress stem cell traits and prostate cancer progression","volume":"48","author":"Zhang","year":"2018","journal-title":"Dev. Cell"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Liu, D., Thakar, M., Aishalalfa, M., Erho, N., Shoag, J., Jenkins, R.B., Karnes, R.J., Shaffer, A.M., Rubin, M.A., and Trock, B. (2018). Impact of the SPOP mutant subtype on the interpretation of clinical parametrs in prostate cancer. JCO Precis. Oncol.","DOI":"10.1200\/PO.18.00036"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1172\/JCI96551","article-title":"SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG","volume":"128","author":"Shoag","year":"2018","journal-title":"J. Clin. Invest."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ccell.2017.02.004","article-title":"SPOP mutation drives prostate tumorigenesis in vivo through coordinate regulation of PI3K\/mTOR and AR signaling","volume":"31","author":"Blattner","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"5585","DOI":"10.1158\/1078-0432.CCR-18-0937","article-title":"SPOP-mutated\/CHD1-deleted lethal prostate cancer and abiraterone sensitivity","volume":"24","author":"Boysen","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/nm.4378","article-title":"Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4","volume":"23","author":"Dai","year":"2017","journal-title":"Net. Med."},{"key":"ref_138","first-page":"345","article-title":"AMPK promotes SPOP-mediated NANOG degradation to regulate prostate cancer cell stemness","volume":"48","author":"Wang","year":"2019","journal-title":"Mol. Cell"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.molcel.2018.08.027","article-title":"Cancer mutations of the tumor suppressor SPOP disrupt the formation of active, phase-separated compartments","volume":"72","author":"Bouchard","year":"2018","journal-title":"Mol. Cell"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature25015","article-title":"Cyclin D-CDK4 kinase destabilizes PD-L1 via Cul3SPOP to control cancer immune surveillance","volume":"553","author":"Zhang","year":"2018","journal-title":"Nature"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.eururo.2017.08.027","article-title":"Whole-genome and transcriptome sequencing of prostate cancer identify new genetic alterations driving disease progression","volume":"73","author":"Ren","year":"2018","journal-title":"Eur. Urol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1093\/nar\/gky128","article-title":"Human CHD1 is required for early DNA-damage signaling and is uniquely regulated by its N terminus","volume":"8","author":"Zhou","year":"2018","journal-title":"Nucleic Acid Res."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1158\/0008-5472.CAN-14-1596","article-title":"Coordinate loss of MAP3K7 and CHD1 promotes aggressive prostate cancer","volume":"75","author":"Rodrigues","year":"2015","journal-title":"Cancer Res."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/pros.22873","article-title":"ERG and CHD1 heterogeneity in prostate cancer: use of confocal microscopy in assessment of microscopic foci","volume":"74","author":"Tereshchenko","year":"2014","journal-title":"Prostate"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nature21357","article-title":"Synthetic essentiality of chromatin remodeling factor CHD1 in PTEN deficient cancer","volume":"542","author":"Zhao","year":"2017","journal-title":"Nature"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/path.4826","article-title":"The molecular undepinnings of prostate cancer: impacts on management and pathology practice","volume":"241","author":"Rodrigues","year":"2017","journal-title":"J. Pathol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.15252\/embr.201642352","article-title":"Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness","volume":"17","author":"Kari","year":"2016","journal-title":"EMBO Rep."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1093\/annonc\/mdx165","article-title":"CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair","volume":"28","author":"Shenoy","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1470-2045(18)30365-6","article-title":"Olaparib combined with abiraterone in patients with metastatic castratrion-resistant prostate cancer: A randomized, double-blind, placebo-controlled, phase 2 trial","volume":"17","author":"Clarke","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1158\/2159-8290.CD-17-0261","article-title":"Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition","volume":"7","author":"Goodall","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"6863","DOI":"10.1158\/1078-0432.CCR-17-0955","article-title":"MSH2 loss in primary prostate cancer","volume":"23","author":"Guedes","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1172\/JCI121924","article-title":"Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer","volume":"128","author":"Rescigno","year":"2018","journal-title":"J. Clin. Invest."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.eururo.2018.10.009","article-title":"Clinical features and therapeutic outcomes in men with advanced prostate cancer and DNA mismatch repair gene mutations","volume":"75","author":"Antonarakis","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/his.13806","article-title":"DNA damage repair alterations are frequent in prostatic adenocarcinomas with focal pleomorphic giant cell features","volume":"74","author":"Lotan","year":"2019","journal-title":"Histopathology"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"a30452","DOI":"10.1101\/cshperspect.a030452","article-title":"Androgen signaling in prostate cancer","volume":"7","author":"Dai","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1038\/bjc.2014.268","article-title":"Androgen metabolism in prostate cancer: From molecular mechanisms to clinical consequences","volume":"111","author":"Chang","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/ng0495-401","article-title":"In vivo amplification of the androgen receptor gene and progression of human prostate cancer","volume":"9","author":"Vikakorpi","year":"1995","journal-title":"Nat. Genet."},{"key":"ref_160","first-page":"314","article-title":"Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer","volume":"57","author":"Koivisto","year":"1997","journal-title":"Cancer Res."},{"key":"ref_161","first-page":"3550","article-title":"Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer","volume":"61","author":"Linja","year":"2001","journal-title":"Cancer Res."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nm972","article-title":"Molecular determinants of resistance to antiandrogen therapy","volume":"10","author":"Chen","year":"2004","journal-title":"Nat. Med."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.cell.2018.05.037","article-title":"A somatically acquired enhancer of the androgen receptor is a noncoding driver in advanced prostate cancer","volume":"174","author":"Takeda","year":"2018","journal-title":"Cell"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cell.2018.05.036","article-title":"Structural alterations driving castration-resistant prostate cancer revealed by linked-read genome sequencing","volume":"174","author":"Viswanathan","year":"2018","journal-title":"Cell"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.cell.2013.07.029","article-title":"A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer","volume":"154","author":"Chang","year":"2013","journal-title":"Cell"},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Fujita, K., and Nonomura, N. (2018). Role of androgen receptor in prostate cancer: A review. World J. Mens Health.","DOI":"10.5534\/wjmh.180040"},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Kita, Y., Goto, T., Akamatsu, S., Yamasaki, T., Inoue, T., Ogawa, O., and Kobayashi, T. (2018). Castration-resistant prostate cancer refractory to second-generation androgen receptor axis-targeted agents: Opportunities and challenges. Cancers, 10.","DOI":"10.3390\/cancers10100345"},{"key":"ref_168","first-page":"2315","article-title":"Androgen receptor gene aberrations in circulating cell-free DNA: biomarker4s of therapeutic resistance in castration-resistant prostate cancer","volume":"21","author":"Azad","year":"2015","journal-title":"Prostate Cancer Res."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1158\/2159-8290.CD-17-0937","article-title":"Circulating tumor DNA genomics correlate with resistance to abiraterone ans enzalutamide in prostate cancer","volume":"8","author":"Annala","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1002\/cncr.31959","article-title":"Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer","volume":"125","author":"Sonpavde","year":"2019","journal-title":"Cancer"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13059-015-0864-1","article-title":"Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients","volume":"17","author":"Lallous","year":"2016","journal-title":"Genome Biol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1158\/1078-0432.CCR-14-1220","article-title":"Abiraterone in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors","volume":"21","author":"Chen","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1158\/2159-8290.CD-13-0226","article-title":"A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509","volume":"3","author":"Joseph","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1158\/2159-8290.CD-13-0142","article-title":"An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide)","volume":"3","author":"Korpal","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"312re10","DOI":"10.1126\/scitranslmed.aac9511","article-title":"Plasma AR and abiraterone-resistant prostate cancer","volume":"7","author":"Romanel","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomized controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nature14406","article-title":"Conversion of abiraterone to D4A drives anti-tumor activity in prostate cancer","volume":"523","author":"Li","year":"2015","journal-title":"Nature"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","article-title":"Phase I clinical trial of a selective inhibitor of cyp17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven","volume":"26","author":"Attard","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S1470-2045(17)30911-7","article-title":"Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-na\u00efve prostate cancer (LATITUDE): An international, randomized phase 3 trial","volume":"19","author":"Chi","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): Final overall survival analysis of a randomized, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/annonc\/mdy072","article-title":"Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: Directly randomized data from the STAMPEDE multi-arm, multi-stage platform protocol","volume":"29","author":"Sydes","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous cxhemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-na\u00efve men with metastatic castration-resistant prostate cancer (COU-AA-302): Final overall survival analysis of a randomized, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.eururo.2016.06.033","article-title":"Subsequent chemotherapy and treatment patterns after abiraterone acetate in patients with metastatic castration-resistant prostate cancer: Post-hoc analysis of COU-AA-302","volume":"71","author":"Smith","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.eururo.2016.07.032","article-title":"Enzalutamide in men with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: Extended analysis of the phase 3 PREVAIL study","volume":"71","author":"Beer","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.juro.2017.08.080","article-title":"Efficacy and safety of enzalutamide vs. Bicalutamide in younger and older patients with metastatic castration resistant prostate cancer in the TERRAIN trial","volume":"199","author":"Siemens","year":"2018","journal-title":"J. Urol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2015.64.9285","article-title":"Enzalutamide versus bicalutamide in castration-resistant prostate cancer: The STRIVE trial","volume":"34","author":"Penson","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","article-title":"Enzalutamide in men with nonmetastatic. Castration-resistant prostate cancer","volume":"378","author":"Hussain","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S1470-2045(18)30898-2","article-title":"Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): A multicenter, randomized, double-blind, phase 3 trial","volume":"20","author":"Tombol","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.eururo.2018.12.015","article-title":"Health-relatyed quality of life for abiraterone plus prednisone versus enzalutamide in patients with metastatic castration-resistant prostate cancer: Results from a phase II randomized trial","volume":"75","author":"Khalaf","year":"2019","journal-title":"Eur. J. Urol."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S1470-2045(18)30860-X","article-title":"Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): A randomized, double-blind, placebo-controlled phase 3 trial","volume":"20","author":"Smith","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumor for newly diagnosed, mertastatic prostate cancer (STAMPEDE): A randomized controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO.2018.77.9827","article-title":"Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment","volume":"36","author":"Attard","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in porstate","volume":"378","author":"Smith","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/S1470-2045(18)30456-X","article-title":"Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the SPARTAN randomized, placebo-controlled, phase 3 trial","volume":"19","author":"Saad","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in nonmetastatic, castration-resistant prostate cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41585-019-0186-2","article-title":"Enzalutamide, Apalutamide, or Dorolutamide; are apples or bananas best for patients?","volume":"16","author":"Higano","year":"2019","journal-title":"Nat. Rev. Urol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"27440","DOI":"10.18632\/oncotarget.4578","article-title":"Galaterone and VNPT55 induce proteosomal degradation of AR\/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenograft in vivo","volume":"6","author":"Ramalimgan","year":"2015","journal-title":"Oncotarget"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"24992","DOI":"10.18632\/oncotarget.25167","article-title":"The novel anti-androgen candidate galaterone, targets deubiquitinating enzymes, USP12 and USP46, to control prostate cancer growth and survival","volume":"9","author":"McClurg","year":"2018","journal-title":"Oncotarget"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1158\/1078-0432.CCR-15-1432","article-title":"Androgen receptor modulation optimized for response (ARMOR) phase I and II studies: Galaterone for the treatment of castration-resistant prostate cancer","volume":"22","author":"Montgomery","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.1158\/1078-0432.CCR-15-2901","article-title":"Tageting androgen receptor activation function-1 with EPI to evercome resistance mechanisms in castration-resistant prostate cancer","volume":"22","author":"Yang","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_209","doi-asserted-by":"crossref","unstructured":"McKay, R.R., Ye, H., Xie, W., Lis, R., Calagua, C., Zhang, Z., Trinh, O.D., Chang, S.L., Harshman, L.C., and Ross, A.E. (2019). Evaluation of intense androgen deprivation before prostatectomy: A randomized phase II trial of enzalutamide and leuprolide with or without abiraterone. J. Clin. Oncol., in press.","DOI":"10.1200\/JCO.18.01777"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1200\/JCO.18.02158","article-title":"Effect of chemotherapy with docetaxel with androgen suppression and radiotherapy for localized high-risk prostate cancer: The randomized phase III NRG oncology RTOG 0521 trial","volume":"37","author":"Rosenthal","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"4716","DOI":"10.1158\/0008-5472.CAN-18-0610","article-title":"Neoadjuvant-intensive androgen deprivation therapy selects for prostate tumor foci with diverse subclonal oncogenic alterations","volume":"78","author":"Sowalsky","year":"2018","journal-title":"Cancer Res."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1001\/jamaoncol.2017.0751","article-title":"Associations of luminal and basal subtyping of prostate cancer with prognosis and response to androgen deprivation therapy","volume":"3","author":"Zhao","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1056\/NEJMoa1807801","article-title":"Radical prostatectomy or watchful waiting in prostate cancer-29-year follow-up","volume":"379","author":"Holmberg","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.cell.2018.07.015","article-title":"Nuclear pores promote lethal prostate cancer by increasing POM121-driven E2F1, MYC, and AR nuclear import","volume":"174","author":"Pippa","year":"2018","journal-title":"Cell"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ccell.2017.09.003","article-title":"Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling","volume":"32","author":"Bluemn","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.ccell.2017.09.011","article-title":"Cellular origin of androgen receptor pathway-independent prostate cancer and implications for therapy","volume":"9","author":"Brennen","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/0008-5472.CAN-08-2764","article-title":"Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer","volume":"69","author":"Hu","year":"2009","journal-title":"Cancer Res."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"37","author":"Antonarakis","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/modpathol.2017.74","article-title":"Androgen-receptor splice variant-7-positive prostate cancer: A novel molecular subtype with markedly worse androgen-deprivation therapy outcomes in newly diagnosed patients","volume":"31","author":"Li","year":"2018","journal-title":"Mod. Pathol."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1200\/JCO.18.01731","article-title":"Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: The PROPHECY study","volume":"37","author":"Armstrong","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.1158\/1078-0432.CCR-17-0017","article-title":"Androgen receptor variant AR-V9 is coexpressed with AR-V7 in prostate cancer metastases and predicts abiraterone resistance","volume":"23","author":"Kohli","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/s41571-018-0085-0","article-title":"Alternative splicing in prostate cancer","volume":"15","author":"Paschalis","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"13668","DOI":"10.1038\/ncomms13668","article-title":"Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer","volume":"7","author":"Henzler","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"E4584","DOI":"10.1073\/pnas.1802415115","article-title":"Histone demethylase JMJD1A promotes alternative splicing of AR variant 7 (AR-V7) in prostate cancer cells","volume":"115","author":"Fan","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1172\/JCI122819","article-title":"Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer","volume":"129","author":"Sharp","year":"2019","journal-title":"J. Clin. Invest."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1200\/JCO.2016.70.1961","article-title":"Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide","volume":"35","author":"Antonorakis","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"125529","DOI":"10.1172\/jci.insight.125529","article-title":"Multiparametric liquid biopsy analysis in metastatic prostate cancer","volume":"4","author":"Hodara","year":"2019","journal-title":"JCI Insight"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1038\/s41598-019-40719-y","article-title":"Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as biomarker for treatment of castration-resistant prostate cancer","volume":"9","author":"Sumiyoshi","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jmoldx.2018.01.008","article-title":"An in-depth evaluation of the validity and logistics surrounding the testing of AR-V7 mRNA expression in circulating tumor cells","volume":"20","author":"Sieuwerts","year":"2018","journal-title":"J. Mol. Diagn."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"6810","DOI":"10.1073\/pnas.1718811115","article-title":"Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13","volume":"115","author":"Chen","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.molcel.2018.08.029","article-title":"ZFX mediates non-canonical oncogenic functions of the androgen receptor splice variant 7 in castrate-resistant prostate cancer","volume":"72","author":"Cai","year":"2018","journal-title":"Mol. Cell"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccell.2019.01.008","article-title":"Arv7 repressees tumor-suppressor genes in catration-resistant prostate cancer","volume":"35","author":"Cato","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1158\/1535-7163.MCT-14-1057","article-title":"NF-kB2\/p52:c-Myc:hnRNPA1 pathway regulates expression of androgen receptor splice variants and enzalutamide sensitivity in prostate cancer","volume":"14","author":"Nadiminty","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1158\/1535-7163.MCT-17-0030","article-title":"Quercetin targets nhRNPA1 to overcome enzalutamide resistance in prostate cancer cells","volume":"16","author":"Tummala","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_235","doi-asserted-by":"crossref","unstructured":"Carabet, L.A., Leblanc, E., Lallous, N., Morin, H., Ghaidi, F., Lee, J., Rennie, P.S., and Cherkasov, A. (2019). Computer-aided discovery of small molecules targeting RNA splicing activity of hnRNP A1 in castration-resistant prostate cancer. Molecules, 14.","DOI":"10.3390\/molecules24040763"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamaoncol.2015.1341","article-title":"Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer","volume":"1","author":"Antonarakis","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.eururo.2015.07.007","article-title":"Efficacy of Cabazitaxel in castration-resistant prostate cancer is independent of the presence of AR-V7 in circulating tumor cells","volume":"68","author":"Onstenk","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1001\/jamaoncol.2018.1621","article-title":"Assessment of the validity of nuclear-localized androgen receptor splice variant 7 in circulating tumor cells as predictive biomarker for castration-resistant prostate cancer","volume":"4","author":"Scher","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1200\/JCO.2017.72.4138","article-title":"Randomized, noncompareative, phase II trial or early switch from docetaxel to cabazitaxel or vice versa, with integrated biomarker analysis, in men with chemotherapy-na\u00efve, metastatic, castration-resistant prostate cancer","volume":"35","author":"Antonarakis","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1158\/1078-0432.CCR-18-0320","article-title":"Expression of AR-V7 and Arv567es in circulating tumor cells correlates with outcomes to taxane therapy in men with metastatic prostate cancer treated in TAXYNERGY","volume":"25","author":"Tagawa","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1158\/0008-5472.CAN-13-2876","article-title":"Androgen receptor splice variants determine taxane sensitivity in prostate cancer","volume":"74","author":"Portella","year":"2014","journal-title":"Cancer Res."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1073\/pnas.1808834116","article-title":"Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer","volume":"116","author":"Zadra","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1158\/1541-7786.MCR-18-1101","article-title":"Whole genome and transcriptional analysis of treatment-emergent small cell neuroendocrine prostate cancer demonstrates intra-class heterogeneity","volume":"17","author":"Aggarwal","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ccr.2011.05.006","article-title":"Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth","volume":"19","author":"Mulholland","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.eururo.2018.11.045","article-title":"Compound genomic alterations of TP53, PTEN, and RB1 tumor suppressors in localized and metastatic prostate cancer","volume":"76","author":"Hamid","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1074\/jbc.M114.607846","article-title":"Crosstalking between androgen and PI3K\/AKT signaling pathways in prostate cancer cells","volume":"290","author":"Lee","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.eururo.2014.10.027","article-title":"PTEN protein loss and clinical outcome for castration-resistant prostate cancer treated with abiraterone acetate","volume":"67","author":"Ferraldeschi","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nature09677","article-title":"SMAD4-dependent barrier contrains prostate cancer growth and metastatic progression","volume":"470","author":"Ding","year":"2011","journal-title":"Nature"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/s41588-018-0318-2","article-title":"Molecular landmarks of tumor hypoxia across cancer types","volume":"51","author":"Bhandari","year":"2019","journal-title":"Nat. Genet."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.eururo.2017.12.023","article-title":"Intermediate endpointrs after postprostectomy radiotherapy: 5-year distant metastasis to predict overall survival","volume":"74","author":"Jackson","year":"2018","journal-title":"Eur. Urol."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.celrep.2014.07.053","article-title":"Hexokinase 2-mediated Warburg effect is required for PTEN-and p53-deficiency-driven prostate cancer growth","volume":"8","author":"Wang","year":"2014","journal-title":"Cell Rep."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.1038\/onc.2014.426","article-title":"Loss of ATF3 promotes AKT activation and prostate cancer development in a PTEN knockout mouse model","volume":"34","author":"Wang","year":"2015","journal-title":"Oncogene"},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ccell.2014.11.008","article-title":"Feedback suppression of PI3KA signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kbeta","volume":"27","author":"Schwartz","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/15384047.2018.1523849","article-title":"Next-generation sequencing of prostate cancer: Genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing","volume":"20","author":"Ikeda","year":"2019","journal-title":"Cancer Biol. Ther."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/cncr.31921","article-title":"Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities","volume":"125","author":"Millis","year":"2019","journal-title":"Cancer"},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/2159-8290.CD-17-0867","article-title":"Identification of PIK3CA mutation as a genetic driver of prostate cancer that cooperates with PTEN loss to accelerate progression and castration-resistant growth","volume":"8","author":"Pearson","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_257","doi-asserted-by":"crossref","unstructured":"Crumbaker, M., Khoja, L., and Joshua, A.M. (2017). AR signaling and the PI3K pathway in prostate cancer. Cancers, 9.","DOI":"10.3390\/cancers9040034"},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.bbcan.2018.09.001","article-title":"PI3K pathway in prostate cancer: All resistant roads lead to PI3K","volume":"1870","author":"Park","year":"2018","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1158\/2159-8290.CD-18-1175","article-title":"Challenges for the clinical development of PI3K inhibitors: Strategies to improve their impact in solid tumors","volume":"9","author":"Hanker","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12943-019-0954-x","article-title":"Targeting PI3K in cancer: Mechanisms and advances in clinical trials","volume":"18","author":"Yang","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1158\/2159-8290.CD-17-1215","article-title":"PTEN deficiency and AMPK activation promote nutrient scavenging and anabolism in prostate cancer cells","volume":"8","author":"Kim","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"5251","DOI":"10.1038\/onc.2013.463","article-title":"Androgens regulate prostate cancer cell growth via an AMPK-PGC-1\u03b1Mediated metabolic switch","volume":"33","author":"Tennakoon","year":"2014","journal-title":"Oncogene"},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"6747","DOI":"10.1158\/0008-5472.CAN-18-0585","article-title":"CAMKK2 promotes prostate cancer independently of AMPK via increased lipogenesis","volume":"78","author":"Penfold","year":"2018","journal-title":"Cancer Res."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"5265","DOI":"10.1038\/s41388-019-0791-9","article-title":"FDPS cooperates with PTEN loss to promote prostate cancer progression through modulation of small GTPases\/AKT axis","volume":"38","author":"Seshacharyulu","year":"2019","journal-title":"Oncogene"},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1093\/ajcp\/aqw111","article-title":"MAGI-2 is a sensitive and specific marker of prostatic adenocarcinoma: A comparison with AMACR","volume":"146","author":"Goldstein","year":"2016","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.humpath.2016.01.003","article-title":"MAGI-2 in prostate cancer: An immohistochemical study","volume":"52","author":"Goldstein","year":"2016","journal-title":"Hum. Pathol."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/pros.23506","article-title":"MAGI2 is an independent predictor of biochemical recurrence in prostate cancer","volume":"78","author":"David","year":"2018","journal-title":"Prostate"},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"13521","DOI":"10.1074\/jbc.M117.788315","article-title":"Transcriptional regulation of the Nkx3.1 gene in prostate luminal stem cell specification and cancer initiation via its 3\u2019 genomic region","volume":"292","author":"Xie","year":"2017","journal-title":"J. Biol. Chem."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1126\/science.aad9512","article-title":"Identification of an NKX3.1-G9a-UTY transcriptional regulatory network that controls prostate differentiation","volume":"352","author":"Dutta","year":"2016","journal-title":"Science"},{"key":"ref_270","first-page":"35139","article-title":"Cooperation of loss of NKX3.1 and inflammation in prostate cancer initiation","volume":"11","author":"Virk","year":"2018","journal-title":"Dis. Model Mechan."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1097\/PAS.0b013e3181e6cbf3","article-title":"NKX3.1 as a marker of prostatic origin in metastatic tumors","volume":"34","author":"Gurel","year":"2010","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"115","DOI":"10.12688\/f1000research.3818.1","article-title":"Systems analysis of the prostate tumor suppressor NKX3.1 supports role in DNA repair and luminal cell differentiation","volume":"3","author":"Yang","year":"2014","journal-title":"F100Res."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ccr.2006.03.031","article-title":"NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss","volume":"9","author":"Lei","year":"2006","journal-title":"Cancer Cell"},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.cell.2018.06.014","article-title":"Risk SNP-mediated promoter-enhancer switching drives prostate cancer through lncRNA PCAT19","volume":"174","author":"Hua","year":"2018","journal-title":"Cell"},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.cell.2018.06.003","article-title":"Biology and clinical implications of the 19q13 aggressive prostate cancer susceptibility locus","volume":"174","author":"Gao","year":"2018","journal-title":"Cell"},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"6063","DOI":"10.1002\/cncr.27689","article-title":"An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy","volume":"118","author":"Antonarakis","year":"2012","journal-title":"Cancer"},{"key":"ref_277","doi-asserted-by":"crossref","unstructured":"Iwata, T., Schultz, D., Hicks, J., Hubbard, G.K., Mutton, L.N., Lotan, T.L., Betehl, C., Lotz, M.T., Yegnasubramanian, S., and Ne Dang, C.V. (2010). MYC overexpression induces prostatic intraepithelial neoplasia and loss of NKX3.1 in mouse luminal epithelial cells. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0009427"},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"5582","DOI":"10.1038\/onc.2013.505","article-title":"ROCK has a crucial role in regulating prostate tumor growth through interaction with c-Myc","volume":"33","author":"Zhangh","year":"2014","journal-title":"Oncogene"},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"7198","DOI":"10.1158\/0008-5472.CAN-14-1490","article-title":"AKT1 and MYC induce distinctive metabolic fingerprints in human prostate cancer","volume":"74","author":"Priolo","year":"2014","journal-title":"Cancer Res."},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.celrep.2014.05.045","article-title":"EZH2-mediated inactivation of IFN-gamma-JAK-STAT1 signaling is an effective therapeutic target in MYC-driven prostate cancer","volume":"8","author":"Wee","year":"2014","journal-title":"Cell Rep."},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1016\/j.ajpath.2010.12.040","article-title":"Alterations in nucleolar structure and gene expression programs in prostatic neoplasia are driven by the MYC oncogene","volume":"178","author":"Koh","year":"2011","journal-title":"Am. J. Pathol."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/path.4980","article-title":"MYC drives overexpression of telomerase RNA (hTR\/TERC) in prostate cancer","volume":"244","author":"Zheng","year":"2018","journal-title":"J. Pathol."},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ebiom.2017.04.006","article-title":"c-Myc antagonizes the transcriptional activity of the androgen receptor in prostate cancer affecting key gene networks","volume":"18","author":"Barfold","year":"2017","journal-title":"EBioMedicine"},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41467-018-08152-3","article-title":"IRE1\u03b1-XBP1s pathway promotes prostate cancer by activating c-MYC signaling","volume":"10","author":"Sheng","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"788","DOI":"10.15252\/emmm.201404509","article-title":"Divergent androgen regulation of unfolded protein response pathways drives prostate cancer","volume":"7","author":"Sheng","year":"2015","journal-title":"EMBO Mol. Med."},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"4616","DOI":"10.1038\/s41467-018-06863-1","article-title":"Germilne variation at 8q24 and prostate cancer risk in men of European ancestry","volume":"9","author":"Matejcic","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as therapeutic strategy to target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nature13229","article-title":"Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer","volume":"510","author":"Asangani","year":"2014","journal-title":"Nature"},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1038\/s41598-019-40518-5","article-title":"Maintenance of MYC expressionpromotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer","volume":"9","author":"Coleman","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"7128","DOI":"10.1073\/pnas.1521738113","article-title":"PROTAC-induced BET protein degradation as a therapy for castration- resistant prostate cancer","volume":"113","author":"Raina","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1158\/1078-0432.CCR-18-3776","article-title":"Functional and mechanistic interrogation of BET bromodomain degraders for the treatment of metastatic castration resistant prostate cancer","volume":"25","author":"Kregel","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1158\/1541-7786.MCR-18-1231","article-title":"The pioneering role of GATA2 in androgen receptor variant regulation is controlled by bromodomain and extraterminal proteins in castrate-resistant prostate cancer","volume":"17","author":"Chaytor","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1172\/JCI44239","article-title":"The retinoblastoma tumor suppressor controls androgen signalling and human prostate cancer progression","volume":"120","author":"Sharma","year":"2010","journal-title":"J. Clin. Invest."},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1158\/0008-5472.CAN-13-1157","article-title":"A transgenic mouse model for early prostate metastasis lymph nodes","volume":"74","author":"Ko","year":"2014","journal-title":"Cancer Res."},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1126\/science.aah4199","article-title":"Rb1 and TRP53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antindrogen resistance","volume":"355","author":"Ku","year":"2017","journal-title":"Science"},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.aah4307","article-title":"SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer","volume":"355","author":"Mu","year":"2017","journal-title":"Science"},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1158\/0008-5472.CAN-16-1589","article-title":"RB loss promotes prostate cancer metastasis","volume":"77","author":"Thangavel","year":"2017","journal-title":"Cancer Res."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"12507","DOI":"10.1038\/s41598-018-30062-z","article-title":"Mutant allele quantification reveals a genetic basis for TP53 mutation-driven castration resistance in prostate cancer cells","volume":"8","author":"Lei","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1158\/1078-0432.CCR-18-1943","article-title":"TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration resistant prostate cancer","volume":"25","author":"Oeyens","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1200\/JCO.2018.36.6_suppl.57","article-title":"P53 as a predictor of clinical outcome in localized prostate cancer","volume":"36","author":"Mahon","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.humpath.2019.02.006","article-title":"TP53 missense mutation is associated with increased tumor-infiltrating T-cells in primary prostate cancer","volume":"87","author":"Kaur","year":"2019","journal-title":"Hum. Pathol."},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/ng.2654","article-title":"Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion","volume":"45","author":"Wang","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"7604","DOI":"10.18632\/oncotarget.24123","article-title":"SOX9 is a driver of aggressive prostate cancer by promoting invasion, cell fate and cytoskeleton alterations and epithelial to mesenchymal transition","volume":"9","author":"Francis","year":"2018","journal-title":"Oncotarget"},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1172\/JCI78815","article-title":"SOX9 drives WNT pathway activation in prostate cancer","volume":"126","author":"Ma","year":"2016","journal-title":"J. Clin. Invest."},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.cell.2018.04.034","article-title":"Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer","volume":"173","author":"Wu","year":"2018","journal-title":"Cell"},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"71317","DOI":"10.18632\/oncotarget.19813","article-title":"Role of PLZF as a tumor suppressor in prostate cancer","volume":"8","author":"Jin","year":"2017","journal-title":"Oncotarget"},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"E2572","DOI":"10.1073\/pnas.1304318110","article-title":"Molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer","volume":"110","author":"Jin","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_308","doi-asserted-by":"crossref","unstructured":"Xiao, G.Q., Unger, P., Yang, Q., Kinoshita, Y., Siungh, K., McMahon, L., Nastiuk, K., Sha, K., Krolewsk, J., and Burstein, D. (2015). Loss of PLZF expression in prostate cancer by immunohistochemistry correlates with tumor aggressiveness and metastasis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0121318"},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1158\/0008-5472.CAN-14-3602","article-title":"PLZF, a tumor suppressor genetically lost in metastatic castration-resistant prostate cancer, is a mediator of resistance to androgen deprivation therapy","volume":"75","author":"Hsieh","year":"2015","journal-title":"Cancer Res."},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1158\/1055-9965.EPI-18-1014","article-title":"Low expression of the androgen-induced tumor suppressor gene PLZF in lethal prostate cancer","volume":"28","author":"Stopsack","year":"2019","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1158\/1078-0432.CCR-13-2265","article-title":"Evidence for molecular differences in prostate cancer between African American and Caucasian Men","volume":"20","author":"Khani","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_312","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ccr.2008.04.016","article-title":"The role of SPINK1 in EGR rearrangement-negative prostate cancers","volume":"13","author":"Tomlins","year":"2008","journal-title":"Cancer Cell"},{"key":"ref_313","doi-asserted-by":"crossref","unstructured":"Faisal, F.A., Kaur, H.B., Tosoian, J.J., Tomlins, S.A., Schaeffer, E.M., and Lotan, T.L. (2019). SPINK1 expression is enriched in African American prostate cancer but is not associated with altered imnmune infiltration or oncologic outcomes post-prostatectomy. Prostate Cancer Prostatic Dis.","DOI":"10.1038\/s41391-019-0139-0"},{"key":"ref_314","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/j.ebiom.2015.10.028","article-title":"A novel genomic alteration of LSAMP associates with aggressive prostate cancer in African American men","volume":"2","author":"Petrovics","year":"2015","journal-title":"EBioMedicine"},{"key":"ref_315","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1158\/0008-5472.CAN-15-1787","article-title":"Mutational landscape of aggressive prostate tumors in African American men","volume":"76","author":"Lindquist","year":"2016","journal-title":"Cancer Res."},{"key":"ref_316","doi-asserted-by":"crossref","first-page":"6726","DOI":"10.1158\/0008-5472.CAN-18-3382","article-title":"Towards greater inclusion in cancer genomics studies","volume":"78","author":"Huang","year":"2018","journal-title":"Cancer Res."},{"key":"ref_317","doi-asserted-by":"crossref","first-page":"6736","DOI":"10.1158\/0008-5472.CAN-18-0254","article-title":"Whole-genome sequencing reveals elevated tumor burden and initiating driver mutations in African men with treatment-na\u00efve, high-risk prostate cancer","volume":"78","author":"Jaratlerdsiri","year":"2018","journal-title":"Cancer Res."},{"key":"ref_318","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.eururo.2018.08.026","article-title":"Mutational profile of aggressive, localized prostate cancer from African Carribean men versus European ancestry men","volume":"75","author":"Tonon","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_319","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/bjc.2011.273","article-title":"Ethnic differences in prostate cancer","volume":"105","author":"Kherandish","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_320","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1001\/jama.2018.11716","article-title":"Prostate cancer-specific mortality across gleason scores in black vs. nonblack men","volume":"320","author":"Mahal","year":"2018","journal-title":"JAMA"},{"key":"ref_321","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.eururo.2019.01.010","article-title":"Prostate cancer genomic-risk differences between African-American and white men across gleason scores","volume":"75","author":"Mahal","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_322","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1200\/JCO.2014.59.8912","article-title":"Novel biomarker signature that may predict aggressive disease in African American men with prostate cancer","volume":"33","author":"Yamoah","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_323","doi-asserted-by":"crossref","first-page":"16335","DOI":"10.1038\/s41598-018-34637-8","article-title":"Dysregulated gene expression predicts tumor aggressivenesss in African-American prostate cancer patients","volume":"8","author":"Ali","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_324","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1002\/cncr.30834","article-title":"Shared Equal Access Regional Cancer Hospital (SEARCH) Database Staudy Group. Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database","volume":"123","author":"Freedland","year":"2017","journal-title":"Cancer"},{"key":"ref_325","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/cncr.31808","article-title":"Does race predict the development of metastases in men who receive androgen-deprivation therapy for a biochemical recurrence after radical prostatectomy?","volume":"125","author":"Vidal","year":"2019","journal-title":"Cancer"},{"key":"ref_326","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"Whittington","year":"1998","journal-title":"JAMA"},{"key":"ref_327","doi-asserted-by":"crossref","first-page":"e484","DOI":"10.1016\/S1470-2045(14)70211-6","article-title":"Prevention and early detecxtion of prostate cancer","volume":"15","author":"Cuzick","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_328","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S1470-2045(10)70295-3","article-title":"Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: A retrospective study","volume":"12","author":"Cuzick","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_329","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/bjc.2012.39","article-title":"Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort","volume":"106","author":"Cuzicz","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_330","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.eururo.2014.05.004","article-title":"A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, a biopsy undersampling","volume":"66","author":"Klein","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_331","doi-asserted-by":"crossref","unstructured":"Erho, N., Crisan, A., Vergara, I.A., Mitra, A.P., Ghadessi, M., Buerki, C., Bergstriath, E.J., Kollmeyer, T., Fink, S., and Haddad, Z. (2013). Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS ONE, 24.","DOI":"10.1371\/journal.pone.0066855"},{"key":"ref_332","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/j.juro.2013.06.017","article-title":"Validation of a genomic classifier that predicts metastasis following radical prostectomy in at risk population","volume":"190","author":"Karnes","year":"2013","journal-title":"J. Urol."},{"key":"ref_333","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.eururo.2014.10.036","article-title":"A genomic classifier improves prediction of mestatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy","volume":"67","author":"Klein","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_334","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eururo.2015.05.042","article-title":"Tissue-based genomic augments post-prostatectomy risk stratification in a natural history cohort of intermediate-and high-risk men","volume":"69","author":"Ross","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_335","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1200\/JCO.2016.70.2811","article-title":"Individual patient-level meta-analysis of the performance of the Decipher Genomic Classifier in high-risk men after prostatectomy to predict development of metastatic disease","volume":"35","author":"Spratt","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_336","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.eururo.2019.01.027","article-title":"Unraveling prostate cancer genomics, pathology, and magnetic resonance imaging visibility","volume":"76","author":"Shoag","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_337","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.eururo.2018.05.014","article-title":"The diverse genomic landscape of clinically low-risk prostate cancer","volume":"74","author":"Cooperberg","year":"2018","journal-title":"Eur. Urol."},{"key":"ref_338","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1200\/JCO.2017.74.2940","article-title":"Development and validation of a novel integrated clinical-genomic risk group classification for lacalized prostate cancer","volume":"36","author":"Spratt","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_339","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/S1470-2045(16)30491-0","article-title":"Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: A matched, retrospective analysis","volume":"17","author":"Zhao","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_340","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.eururo.2017.09.013","article-title":"A biopsy-based 17-gene genomic prostate score as a predictor of metastases and prostate cancer death in surgically treated men with clinically localized disease","volume":"73","author":"Lu","year":"2018","journal-title":"Eur. Urol."},{"key":"ref_341","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.eururo.2014.11.030","article-title":"A biopsy-based 17-gene genomic prostate score predicts recurrence after radical prostectomy and adverse surgical pathology in a racially diverse population of men with clinically low- and intermediate-risk prostate cancer","volume":"68","author":"Cullen","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_342","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1073\/pnas.0304146101","article-title":"Gene expression profiling identifies clinically relevant subtypes of prostate cancer","volume":"101","author":"Lapointe","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_343","doi-asserted-by":"crossref","first-page":"8504","DOI":"10.1158\/0008-5472.CAN-07-0673","article-title":"Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis","volume":"67","author":"Lapointe","year":"2007","journal-title":"Cancer Res."},{"key":"ref_344","doi-asserted-by":"crossref","first-page":"21276","DOI":"10.1073\/pnas.1117029108","article-title":"Molecular classification of prostate cancer using curated expression signatures","volume":"108","author":"Markert","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_345","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/ng.127","article-title":"An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors","volume":"40","author":"Thomson","year":"2008","journal-title":"Nat. Genet."},{"key":"ref_346","doi-asserted-by":"crossref","unstructured":"Rye, M.B., Bertilsson, H., Drablos, F., Angelsen, A., Bathen, T., and Tessem, M.B. (2014). Gene signatures ESC, MYC and ERG-fusion are early markers of a potentially dangerous subtype of prostate cancer. BMC Med. Genom., 7.","DOI":"10.1186\/1755-8794-7-50"},{"key":"ref_347","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.2147\/OTT.S127317","article-title":"The association between SPINK1 and clinical outcomes in patients with prostate cancer: A systematic review and meta-analysis","volume":"10","author":"Zhang","year":"2017","journal-title":"Onco Targets Ther."},{"key":"ref_348","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ccell.2017.10.008","article-title":"Aberrant activation of a gastrointestinal transcriptional circuit in prostate cancer mediates castration resistance","volume":"32","author":"Shukla","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_349","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1158\/1078-0432.CCR-18-3230","article-title":"Epigenetic silencing of miRNA-338-5p and miRNA-421 drives SPINK1-positive prostate cancer","volume":"25","author":"Bhatia","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_350","doi-asserted-by":"crossref","first-page":"E6544","DOI":"10.1073\/pnas.1518007112","article-title":"A basal stem cell signature identifies aggressive prostate cancer phenotypes","volume":"112","author":"Smith","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_351","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","article-title":"Supervised risk predictor of breast cancer based on intrinsic subtypes","volume":"27","author":"Parker","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_352","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1158\/1078-0432.CCR-18-3121","article-title":"Clinical and genomic implications of luminal and basal subtypes across carcinomas","volume":"25","author":"Zhao","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_353","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/0008-5472.CAN-16-0902","article-title":"Integrated classification of prostate cancer reveals a novel luminal subtype with poor outcome","volume":"76","author":"You","year":"2016","journal-title":"Cancer Res."},{"key":"ref_354","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.cell.2009.04.056","article-title":"Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer","volume":"138","author":"Wang","year":"2009","journal-title":"Cell"},{"key":"ref_355","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ccr.2012.11.010","article-title":"The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man","volume":"23","author":"Sharma","year":"2013","journal-title":"Cancer Cell"},{"key":"ref_356","doi-asserted-by":"crossref","first-page":"502","DOI":"10.15252\/embj.201490306","article-title":"Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer","volume":"34","author":"Chen","year":"2015","journal-title":"EMBO J."},{"key":"ref_357","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.15252\/emmm.201505424","article-title":"Androgen receptor profiling predicts prostate cancer outcome","volume":"7","author":"Stelloo","year":"2015","journal-title":"EMBO Mol. Med."},{"key":"ref_358","doi-asserted-by":"crossref","first-page":"8954","DOI":"10.1073\/pnas.1805337115","article-title":"Classification of prostate cancer using a protease activity nanosensor library","volume":"115","author":"Dudani","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_359","doi-asserted-by":"crossref","unstructured":"Perera, M., Papa, N., Roberts, M., Williams, M., Udovicich, C., Vela, I., Chrisrtidis, D., Bolton, D., Hofman, M.S., and Lawrentschuk, N. (2019). Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity and distribution of prostate-specific membrane antigen-avid lesions: A systematic review and meta-analysis. Eur. Urol., in press.","DOI":"10.1016\/j.eururo.2019.01.049"},{"key":"ref_360","doi-asserted-by":"crossref","first-page":"E4473","DOI":"10.1073\/pnas.1802354115","article-title":"Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer","volume":"115","author":"Lee","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_361","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41388-018-0488-5","article-title":"A molecular portrait of epithelial-mesenchymal plasticity in prostate cancer associated with clinical outcome","volume":"38","author":"Stylianou","year":"2019","journal-title":"Oncogene"},{"key":"ref_362","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1016\/j.ajpath.2014.06.030","article-title":"Single-cell genetic analysis reveals insights into clonal development of prostate cancers and indicates loss of PTEN as a marker of poor prognosis","volume":"184","author":"Bradley","year":"2014","journal-title":"Am. J. Pathol."},{"key":"ref_363","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nrurol.2018.9","article-title":"Clinical implications of PTEN loss in prostate cancer","volume":"15","author":"Jamaspishvili","year":"2018","journal-title":"Nat. Rev. Urol."},{"key":"ref_364","doi-asserted-by":"crossref","first-page":"65566","DOI":"10.18632\/oncotarget.19217","article-title":"PTEN loss detection in prostate cancer: Comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort","volume":"8","author":"Lotan","year":"2017","journal-title":"Oncotarget"},{"key":"ref_365","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/modpathol.2014.85","article-title":"PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostectomy","volume":"28","author":"Lotan","year":"2015","journal-title":"Mod. Pathol."},{"key":"ref_366","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.eururo.2015.04.033","article-title":"Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes","volume":"68","author":"Tomlins","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_367","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1038\/ncomms6548","article-title":"ERG induces taxane resistance in castration-resistant prostate cancer","volume":"5","author":"Galletti","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_368","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/S1470-2045(14)71021-6","article-title":"Tumor genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: A retrospective cohort study","volume":"15","author":"Lalonde","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_369","doi-asserted-by":"crossref","first-page":"4900","DOI":"10.1038\/s41467-018-07270-2","article-title":"Integrative epigenetic taxonomy of primary prostate cancer","volume":"9","author":"Stelloo","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_370","doi-asserted-by":"crossref","first-page":"5201","DOI":"10.1038\/s41467-018-07511-4","article-title":"NSD2 is a conserved driver of metastatic prostate cancer progression","volume":"9","author":"Aytes","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_371","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40169-017-0138-5","article-title":"Integrating phosphoproteomics into the clinical management of prostate cancer","volume":"6","author":"Cheng","year":"2017","journal-title":"Clin. Transl. Med."},{"key":"ref_372","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/s41585-018-0014-0","article-title":"Personalisation of prostate cancer therapy through phosphoproteomics","volume":"15","author":"Yang","year":"2018","journal-title":"Nat. Rev. Urol."},{"key":"ref_373","doi-asserted-by":"crossref","first-page":"E4762","DOI":"10.1073\/pnas.1319948110","article-title":"Metastatic castration-resistant prostate cancer reveals intrapatient similarity and intrapatient heterogeneity of therapeutic kinase targets","volume":"110","author":"Drake","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_374","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.cell.2016.07.007","article-title":"Phosphoproteome integration reveals patient-specific networks in prostate cancer","volume":"166","author":"Drake","year":"2016","journal-title":"Cell"},{"key":"ref_375","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.eururo.2015.10.053","article-title":"The proteome of primary prostate cancer","volume":"69","author":"Wikstrom","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_376","unstructured":"Thysell, E., Vidman, L., Ylitalo, E.B., Jernberg, E., Crnalic, S., Iglesias-Gato, D., Flores-Morales, A., Stattin, P., Egevad, L., and Widmark, A. (2019). The proteome of prostate cancer bone metastasis reveals heterogeneity with prognostic implications. Mol. Oncol."},{"key":"ref_377","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/s41467-018-03573-6","article-title":"Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression","volume":"9","author":"Latonen","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_378","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.ccell.2019.02.005","article-title":"The proteogenomic landscape of curable prostate cancer","volume":"35","author":"Sinha","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_379","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2010.10.019","article-title":"PCA3: From basic molecular science to the clinical lab","volume":"301","author":"Day","year":"2011","journal-title":"Cancer Lett."},{"key":"ref_380","doi-asserted-by":"crossref","first-page":"25776","DOI":"10.1038\/srep25776","article-title":"Evaluation of prostate cancer antigen 3 for detecting prostate cancer: A systematic review and meta-analysis","volume":"6","author":"Cui","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_381","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrurol.2011.10","article-title":"Diagnostic performance of the PCA3 urine test","volume":"8","author":"Lee","year":"2011","journal-title":"Nat. Rev. Urol."},{"key":"ref_382","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/s41585-019-0178-2","article-title":"Merging new-age biomarkers and naniodiagnostics for precision prostate cancer management","volume":"16","author":"Koo","year":"2019","journal-title":"Nat. Rev. Urol."},{"key":"ref_383","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1038\/ng.2771","article-title":"The long noncoding SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI\/SNF complex","volume":"45","author":"Presner","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_384","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/S1470-2045(14)71113-1","article-title":"RNA biomarkers associatyed with metastatic progression in prostate cancer: A multi-institutional high-throughput analysis of SChLAP1","volume":"15","author":"Presner","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_385","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.eururo.2015.12.003","article-title":"Overexpression of the long non-coding RNA SChLAP1 independently predicts lethal prostate cancer","volume":"70","author":"Mehra","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_386","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.eururo.2017.04.034","article-title":"A prostate cancer \u201cnimbous\u201d genomic instability and Schlap1 dysregulation underpin aggression of intraductal and cribiform subpathologies","volume":"72","author":"Chua","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_387","doi-asserted-by":"crossref","first-page":"11428","DOI":"10.1073\/pnas.1902651116","article-title":"Genomic correlates of clinical outcome in advanced prostate cancer","volume":"116","author":"Abida","year":"2019","journal-title":"Proc. Natl. Acad. Sci USA"},{"key":"ref_388","first-page":"405","article-title":"Genomic drivers of poor prognosis and enzalutamide resistance in metastatic castration-resistant prostate cancer","volume":"2","author":"Chen","year":"2019","journal-title":"Eur. Urol. Oncol."},{"key":"ref_389","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2217\/imt-2018-0159","article-title":"Prostate cancer: Any room left for immunotherapies?","volume":"11","author":"Baxevanis","year":"2019","journal-title":"Immnutherapy"},{"key":"ref_390","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.molcel.2018.10.034","article-title":"Phosphorylated RB promotes cancer immunity by inhibiting NF-kB activation and PD-L1 expression","volume":"73","author":"Jin","year":"2019","journal-title":"Mol. Cell"},{"key":"ref_391","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1126\/scitranslmed.aav4810","article-title":"Clinical implications of tumor-intrinsic mechanisms regulating PD-L1","volume":"11","author":"Prestipino","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_392","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1158\/1078-0432.CCR-15-2042","article-title":"The immune checkpoint regulator PD-L1 is highly expressed in aggressive primary prostate cancer","volume":"22","author":"Gevensleben","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_393","doi-asserted-by":"crossref","first-page":"79943","DOI":"10.18632\/oncotarget.13161","article-title":"PD-l1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy","volume":"29","author":"Gevensleben","year":"2016","journal-title":"Oncotarget"},{"key":"ref_394","first-page":"26789","article-title":"The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-1) in a large, multicenter prostate cancer cohort","volume":"8","author":"Ness","year":"2017","journal-title":"Oncoratget"},{"key":"ref_395","doi-asserted-by":"crossref","first-page":"6812","DOI":"10.1158\/1078-0432.CCR-17-0807","article-title":"Expression of PD-L1 in hormone-na\u00efve and treated prostate cancer patients receiving neoadjuvant abiraterone acetate plus prednisone and leuprolide","volume":"23","author":"Calagua","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_396","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.ajpath.2018.02.014","article-title":"Comprehensive evaluation of programmed death-ligand 1 expression in primary and metastatic prostate cancer","volume":"188","author":"Haffner","year":"2018","journal-title":"Am. J. Pathol."},{"key":"ref_397","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3389\/fphar.2018.01494","article-title":"The clinicopathologic and prognostic significance of programmed cell death ligand 1 (PD-L1) expression in patients with prostate cancer: A systematic review and meta-analysis","volume":"9","author":"Li","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_398","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/jnci\/djy141","article-title":"The immune landscape of prostate cancer and nomination of PD-L2 as a potential therapeutic target","volume":"111","author":"Zhao","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_399","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.eururo.2016.07.033","article-title":"Subgroups of castration- resistant prostate cancer bone metastases defined through an invcerse relationship between androgen receptor activity and immune response","volume":"71","author":"Ylatalo","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_400","doi-asserted-by":"crossref","unstructured":"Venturini, N.J., and Drake, C.G. (2019). Immunotherapy for prostate cancer. Cold Spring Harb. Persp. Med., 9.","DOI":"10.1101\/cshperspect.a030627"},{"key":"ref_401","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1200\/JCO.2005.04.5252","article-title":"Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer","volume":"24","author":"Small","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_402","doi-asserted-by":"crossref","unstructured":"Dutcher, G., and Bilen, M.A. (2018). Therapeutic vaccines for genitourinary malignancies. Vaccines, 6.","DOI":"10.3390\/vaccines6030055"},{"key":"ref_403","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicenter, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_404","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1200\/JCO.2016.69.1584","article-title":"Randomised, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-na\u00efve castration-resistant prostate cancer","volume":"35","author":"Beer","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_405","doi-asserted-by":"crossref","first-page":"28561","DOI":"10.18632\/oncotarget.25564","article-title":"Ipilimumab plus nivolumab and DNA-repait defects in AR-V7-expressing metastatic prostate cancer","volume":"19","author":"Boudadi","year":"2018","journal-title":"Oncotarget"},{"key":"ref_406","doi-asserted-by":"crossref","first-page":"52810","DOI":"10.18632\/oncotarget.10547","article-title":"Early evidence if anti-PD-1 activity in enhzalutamide-resistant prostate cancer","volume":"7","author":"Graff","year":"2016","journal-title":"Oncotarget"},{"key":"ref_407","doi-asserted-by":"crossref","first-page":"5007","DOI":"10.1200\/JCO.2018.36.15_suppl.5007","article-title":"KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC)","volume":"36","author":"Goh","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_408","doi-asserted-by":"crossref","first-page":"T297","DOI":"10.1530\/ERC-17-0145","article-title":"Androgen deprivation and immunotherapy for the treatment of prostate cancer","volume":"24","author":"Garmat","year":"2017","journal-title":"Endocr. Rel. Cancer"},{"key":"ref_409","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1200\/JCO.2018.36.15_suppl.5047","article-title":"Pembrolizumab (Pembro) plus enzalutamide (Enz) in metastatic castration resistant prostate cancer (mCRPC): Extended follow up","volume":"36","author":"Graff","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_410","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nm.4308","article-title":"VISTA in an inhibitory immune checkpointy that is increased after ipilimumab therapy in patients with prostate cancer","volume":"23","author":"Gao","year":"2017","journal-title":"Nat. Med."},{"key":"ref_411","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41586-018-0266-0","article-title":"IL-23 secreted by myeloid cells drives castration-resistant prostate cancer","volume":"559","author":"Calcinotto","year":"2018","journal-title":"Nature"},{"key":"ref_412","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nature21676","article-title":"Effective combinatorial immunotherapy for castrationb-resistant prostate cancer","volume":"543","author":"Lu","year":"2017","journal-title":"Nature"},{"key":"ref_413","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1634\/theoncologist.2018-0819","article-title":"A new molecular taxonomy to predict immune checkpoint inhibitor sensitivity in prostate cancer","volume":"24","author":"Antonarakis","year":"2019","journal-title":"Oncologist"},{"key":"ref_414","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s40425-018-0341-y","article-title":"Microsatellite instability in prostate cancer by PCR or next-generation sequencing","volume":"2","author":"Hampelmann","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_415","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","article-title":"Germile BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer","volume":"3","author":"Castro","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_416","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.eururo.2014.10.022","article-title":"Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localized prostate cancer","volume":"66","author":"Castro","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_417","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.eururo.2018.09.021","article-title":"Germline mutations in ATM and BRCA1\/2 are associated with grade reclassification in men on active surveillance for prostate cancer","volume":"75","author":"Carter","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_418","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41585-019-0164-8","article-title":"The influence of BRCA2 mutation on localized prostate cancer","volume":"16","author":"Taylor","year":"2019","journal-title":"Nat. Rev. Urol."},{"key":"ref_419","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.eururo.2017.02.023","article-title":"Treatment outcomes and tumor loss of heterozygosity in germline DNA repair-deficient prostate cancer","volume":"72","author":"Annala","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_420","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.eururo.2018.01.035","article-title":"Germline DNA-repair gene mutations and outcomnes in men with metastatic castration-resistant prostate cancer receiving first-line abiraterone and enzalutamide","volume":"74","author":"Antonarakis","year":"2018","journal-title":"Eur. Urol."},{"key":"ref_421","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.eururo.2018.01.010","article-title":"Clinical outcome of prostate cancer patients with germline DNA repair mutations: Retrospective analysis from an international study","volume":"73","author":"Mateo","year":"2018","journal-title":"Eur. Urol."},{"key":"ref_422","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1200\/JCO.18.00358","article-title":"PROREPAIR-B: A prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer","volume":"37","author":"Castro","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_423","doi-asserted-by":"crossref","unstructured":"Marshall, C.H., Sokolova, A.O., McNatty, A.L., Cheng, H.H., Eisenberger, M.A., Bryce, A.H., Schweizer, M.T., and Antonarakis, E.S. (2019). Differential response to olaparib treatment among men with metastatic castration-resistant prostate cancer harboring BRCA1 or BRCA2 versus ATM mutations. Eur. Urol.","DOI":"10.1016\/j.eururo.2019.02.002"},{"key":"ref_424","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41391-018-0086-1","article-title":"Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: Association of Gleason score and tumor stage","volume":"22","author":"Marshall","year":"2019","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_425","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.molcel.2018.06.034","article-title":"The biogenesis, functions, and challenges of circular RNAs","volume":"71","author":"Li","year":"2018","journal-title":"Mol. Cell"},{"key":"ref_426","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.cell.2018.12.021","article-title":"The landscape of circular RNA in cancer","volume":"176","author":"Vo","year":"2019","journal-title":"Cell"},{"key":"ref_427","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.cell.2019.01.025","article-title":"Widespread and functional RNA circularization in localized prostate cancer","volume":"176","author":"Chen","year":"2019","journal-title":"Cell"},{"key":"ref_428","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.bbrc.2017.07.162","article-title":"Androgen-responsive circular RNA circSMARCA5 is up-regulated and promotes cell proliferation in prostate cancer","volume":"493","author":"Kong","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_429","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.ijbiomac.2018.09.076","article-title":"Upregulated circular RNA circ-102004 that promotes cell proliferation in prostate cancer","volume":"122","author":"Tu","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_430","doi-asserted-by":"crossref","first-page":"12182","DOI":"10.1073\/pnas.0804700105","article-title":"Androgen receptor is a tumor suppressor and proliferator in prostate cancer","volume":"105","author":"Niu","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_431","doi-asserted-by":"crossref","first-page":"12188","DOI":"10.1073\/pnas.0804701105","article-title":"Targeting the stromal androgen receptor in primary prostate tumors at earlier stages","volume":"105","author":"Niu","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_432","doi-asserted-by":"crossref","first-page":"7962","DOI":"10.1073\/pnas.1105243108","article-title":"Role of autonomous androgen receptor signaling in prostate cancer initiation is dichotomous and depends on the oncogenic signal","volume":"108","author":"Memarzadeh","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_433","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/pros.21043","article-title":"Cell autonomous intracellular androgen receptor signaling drives the growth of human prostate cancer initiating cells","volume":"70","author":"Gurel","year":"2010","journal-title":"Prostate"},{"key":"ref_434","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nmeth855","article-title":"Formation of human prostate tissue from embryonic stem cells","volume":"3","author":"Taylor","year":"2006","journal-title":"Nat. Methods"},{"key":"ref_435","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1210\/en.2010-1377","article-title":"Estrogen-initiated transformation of prostate epithelium derived from normal human prostate stem-progenitor cells","volume":"152","author":"Hu","year":"2011","journal-title":"Endocrinology"},{"key":"ref_436","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1073\/pnas.0911651107","article-title":"Local prolactin is a target to prevent expansion of basal\/stem cells in prostate tumors","volume":"107","author":"Rouet","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_437","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1016\/j.ajpath.2014.07.020","article-title":"Prolactin-induced prostate tumorigenesis links sustained Stat5 signaling with the amplification of basal\/stem cells and emergence of putative luminal progenitors","volume":"184","author":"Chiche","year":"2014","journal-title":"Am. J. Pathol."},{"key":"ref_438","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1158\/1535-7163.MCT-10-0850","article-title":"Transcription factor Stat5 knockdown enhances receptor androgen degradation and delays castration-resistant prostate cancer progression in vivo","volume":"10","author":"Thomas","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"ref_439","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.1158\/1078-0432.CCR-13-0422","article-title":"Pharmacologic inhibition of Jak2-Stat5 signaling by Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancer","volume":"19","author":"Gu","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_440","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1158\/1535-7163.MCT-14-0819","article-title":"Inhibition of Stat5a\/b enhances proteasomal degradation of androgen receptor liganded by antiandrogens in prostate cancer","volume":"14","author":"Hoang","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_441","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1016\/j.ajpath.2015.04.026","article-title":"Jak2-Stat5a\/b signaling induces epithelial-to-mesenchymal transition and stem-like cell properties in prostate cancer","volume":"185","author":"Talati","year":"2015","journal-title":"Am. J. Pathol."},{"key":"ref_442","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.humpath.2012.06.001","article-title":"Nuclear Stat5a\/b predicts early recurrence and prostate cancer-specific death in patients treated by radical prostatectomy","volume":"44","author":"Mirtti","year":"2013","journal-title":"Hum. Pathol."},{"key":"ref_443","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/j.ajpath.2013.02.044","article-title":"STAT5A\/B gene locus undergoes amplification during human prostate cancer progression","volume":"182","author":"Haddad","year":"2013","journal-title":"Am. J. Pathol."},{"key":"ref_444","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1158\/1078-0432.CCR-17-2768","article-title":"STAT5A\/B blockade sensitizes prostate cancer to radiation through inhibition of RAD51 and DNA repair","volume":"24","author":"Maranto","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_445","first-page":"33","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"10","author":"Watson","year":"2004","journal-title":"Nat. Med."},{"key":"ref_446","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/ncpuro1296","article-title":"Androgen deprivation therapy: Progress in understanding mechanisms of resistance and optimizing androgen depletion","volume":"6","author":"Harris","year":"2009","journal-title":"Nat. Clin. Pract. Urol."},{"key":"ref_447","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S0046-8177(03)00190-4","article-title":"Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone","volume":"34","author":"Roudier","year":"2003","journal-title":"Hum. Pathol."},{"key":"ref_448","doi-asserted-by":"crossref","first-page":"9209","DOI":"10.1158\/0008-5472.CAN-04-2442","article-title":"Androgen-independent prostate cancer is a heterogeneous group of diseases: Lessons from a rapid autopsy program","volume":"64","author":"Shah","year":"2004","journal-title":"Cancer Res"},{"key":"ref_449","doi-asserted-by":"crossref","first-page":"23959","DOI":"10.18632\/oncotarget.4260","article-title":"Systematic dissection of phenotypic, functional, and tumorigenic heterogeneity of human prostate cancer cells","volume":"6","author":"Liu","year":"2015","journal-title":"Oncotarget"},{"key":"ref_450","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1038\/s41467-018-06067-7","article-title":"Linking prostate cancer AR heterogeneity to distinct castration and ezalutamide responses","volume":"9","author":"Li","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_451","doi-asserted-by":"crossref","unstructured":"Finones, R.R., Yeargin, J., Lee, M., Kaur, A.P., Cheng, C., Sun, P., Wu, C., Nguyen, C., Wang-Rodriguez, J., and Meyer, A.N. (2013). Early human prostate adenocarcinomas harbor androgen-independent cancer cells. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0074438"},{"key":"ref_452","first-page":"28","article-title":"The matabolic landscape of prostate cancer","volume":"2","author":"Giunchi","year":"2019","journal-title":"Eur. Oncol."},{"key":"ref_453","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/j.bbalip.2013.03.010","article-title":"The fat side of prostate cancer","volume":"1831","author":"Zandra","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_454","doi-asserted-by":"crossref","first-page":"a030569","DOI":"10.1101\/cshperspect.a030569","article-title":"Metabolic vulnerabilities of prostate cancer: Diagnostic and therapeutic opportunities","volume":"8","author":"Zadra","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_455","doi-asserted-by":"crossref","first-page":"R219","DOI":"10.1530\/ERC-15-0556","article-title":"Androgen control of lipid metabolism in prostate cancer: Novel insights and future applications","volume":"23","author":"Butler","year":"2016","journal-title":"Endocr. Telat. Cancer"},{"key":"ref_456","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41588-017-0026-3","article-title":"Compatmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer","volume":"50","author":"Chen","year":"2018","journal-title":"Nat. Genet."},{"key":"ref_457","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1158\/1541-7786.MCR-18-0347","article-title":"Extracellular fatty acids are the major contributor to lipid synthesis in prostate cancer","volume":"17","author":"Balaban","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"ref_458","first-page":"1262","article-title":"Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resitant tumor growth","volume":"67","author":"Montgomewry","year":"2008","journal-title":"Cancer Res."},{"key":"ref_459","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41588-017-0027-2","article-title":"An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer","volume":"50","author":"Chen","year":"2018","journal-title":"Nat. Genet."},{"key":"ref_460","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/onc.2017.385","article-title":"Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer","volume":"37","author":"Han","year":"2018","journal-title":"Oncogene"},{"key":"ref_461","doi-asserted-by":"crossref","first-page":"14328","DOI":"10.1074\/jbc.RA118.004442","article-title":"Inhibition of cholesterol biosynthesis overcomes enzalutamide resistance in castration-resistant prostate cancer (CRPC)","volume":"293","author":"Kong","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_462","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1158\/0008-5472.CAN-18-2529","article-title":"Upregulation of scavenger receptor B1 is required for steroidogenic and non-steroidogenic cholesterol metabolism in prostate cancer","volume":"79","author":"Gordon","year":"2019","journal-title":"Cancer Res."},{"key":"ref_463","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s42255-018-0002-y","article-title":"Mitochondrial pyruvate import is a metabolic vulnerability in androgen receptor-driven prostate cancer","volume":"1","author":"Bader","year":"2019","journal-title":"Nat. Metab."},{"key":"ref_464","doi-asserted-by":"crossref","first-page":"11612","DOI":"10.1038\/ncomms11612","article-title":"Inhibition of the hexosamine biosynthetic pathway promotes castration-resistant prostate cancer","volume":"7","author":"Kaushik","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_465","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/path.4518","article-title":"Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth anf tumour development","volume":"236","author":"Wang","year":"2015","journal-title":"J. Pathol."},{"key":"ref_466","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1158\/1541-7786.MCR-16-0480","article-title":"Glutamine transporters are targets of multiple oncogenic signaling pathways in prostate cancer","volume":"15","author":"White","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"ref_467","doi-asserted-by":"crossref","first-page":"16159","DOI":"10.1038\/s41598-017-16327-z","article-title":"Metabolic differences in glutamine utilization lead to metaboliuc vulnerabilities in prostate cancer","volume":"7","author":"Zacharias","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_468","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1172\/JCI99397","article-title":"Stromal epigenetic alterations drive metabolic and neuroendocrine prostate cancer reprogramming","volume":"128","author":"Mishra","year":"2018","journal-title":"J. Clin. Invest."},{"key":"ref_469","doi-asserted-by":"crossref","unstructured":"Gonthier, K., Poluri, R.T.K., Weidmann, C., Tadros, M., and Audet-Walsh, E. (2019). Reprogramming of isocitrate dehydrogenase expression and activity by the androgen receptor in prostate cancer. Mol. Cancer Res.","DOI":"10.1158\/1541-7786.MCR-19-0020"},{"key":"ref_470","doi-asserted-by":"crossref","first-page":"4972","DOI":"10.1038\/s41467-018-07411-7","article-title":"Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen\/AR-targeted therapy","volume":"9","author":"Geng","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_471","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.1172\/JCI96268","article-title":"Targeted hypoxiua reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy","volume":"128","author":"Jayaprakash","year":"2018","journal-title":"J. Clin. Invest."},{"key":"ref_472","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1016\/j.celrep.2018.11.086","article-title":"A cellular anatomy of the normal adult human prostate and prostatic urethra","volume":"25","author":"Henry","year":"2018","journal-title":"Cell Rep."},{"key":"ref_473","unstructured":"Rodgers, C.H., Coffey, D.S., Cunha, G., Grayshack, J.T., Henman, R., and Horton, R. (1987). Control of cell proliferation and cell death in the normal and neoplastic prostate: A stem cell model, Bening Prostatic Hyperplasia."},{"key":"ref_474","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1210\/jc.2002-022038","article-title":"Is the Achille\u2019s heel for prostate cancer cancer therapy a gain of function in androgen receptor signaling?","volume":"88","author":"Litvinov","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_475","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1083\/jcb.200202067","article-title":"Proximal location of mouse prostate epithelial stem cells: A model of prostatic homeostasis","volume":"157","author":"Tsujimura","year":"2002","journal-title":"J. Cell Biol."},{"key":"ref_476","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/onc.2010.530","article-title":"Revisiting the concept of cancer stem cells in prostate cancer","volume":"30","author":"Wang","year":"2011","journal-title":"Oncogene"},{"key":"ref_477","doi-asserted-by":"crossref","first-page":"17745","DOI":"10.1074\/jbc.M115.661033","article-title":"Prostate sphere-forming stem cells are derived from the P63-expressing basal compartment","volume":"290","author":"Huang","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_478","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nprot.2016.006","article-title":"Organoid culture systems for prostate epithelial and cancer tissue","volume":"11","author":"Drost","year":"2016","journal-title":"Nat. Protoc."},{"key":"ref_479","doi-asserted-by":"crossref","unstructured":"Li, J.J., and Shen, M.M. (2018). Prostate stem cells and cancer stem cells. CSH Perspect. Med.","DOI":"10.1101\/cshperspect.a030395"},{"key":"ref_480","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1242\/jcs.114.21.3865","article-title":"Identification and isolation of human prostate epithelial stem cells based on alpha(2)beta(1)-integrin expression","volume":"114","author":"Collins","year":"2001","journal-title":"J. Cell Sci."},{"key":"ref_481","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1242\/jcs.01222","article-title":"CD133, a novel marker for human prostatic epithelial stem cells","volume":"117","author":"Richardson","year":"2004","journal-title":"J. Cell Sci."},{"key":"ref_482","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/pros.21083","article-title":"Human prostate sphere-forming cells represent a subset of basal epithelial cells capable of glandular regeneration in vivo","volume":"70","author":"Garraway","year":"2010","journal-title":"Prostate"},{"key":"ref_483","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/embor.2012.169","article-title":"A plethora of progenitors in the post-natal prostate","volume":"13","author":"Goldstein","year":"2012","journal-title":"EMBO Rep."},{"key":"ref_484","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/nature07427","article-title":"Generation of a prostate from a single adult stem cell","volume":"456","author":"Leong","year":"2008","journal-title":"Nature"},{"key":"ref_485","doi-asserted-by":"crossref","first-page":"20882","DOI":"10.1073\/pnas.0811411106","article-title":"Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics","volume":"105","author":"Goldstein","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_486","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.stem.2010.11.013","article-title":"Bmi-1 is a crucial regulator of prostate stem cell renewal and malignant transformation","volume":"7","author":"Lukacs","year":"2010","journal-title":"Cell Stem Cell"},{"key":"ref_487","first-page":"4756","article-title":"Symmetrical and asymmetrical division analysis provides evidence for a hierarchy of prostate epitrhelial cell lineages","volume":"5","author":"Wang","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_488","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.stemcr.2015.04.003","article-title":"Castration-resistant Lgr5(+) cells are long-lived stem cells required for prostatic regeneration","volume":"4","author":"Wang","year":"2015","journal-title":"Stem Cell Rep."},{"key":"ref_489","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.stemcr.2016.03.007","article-title":"Basal progenitors contribute to repair of the propstate epitheliumn following induced luminal anoikis","volume":"6","author":"Toivanen","year":"2016","journal-title":"Stem Cell Rep."},{"key":"ref_490","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.celrep.2017.07.061","article-title":"Multipotent basal stem cell cells, maintained in localized proximal niches, support directed long-ranging epithelial flows in human prostates","volume":"20","author":"Moad","year":"2017","journal-title":"Cell Rep."},{"key":"ref_491","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.scr.2017.06.009","article-title":"Isolation and functional interrogation of adult human prostate epithelial stem cells at single cell resolution","volume":"23","author":"Hu","year":"2017","journal-title":"Stem Cell Res."},{"key":"ref_492","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature08361","article-title":"A luminal epithelial stem cell that is a cell of origin for prostate cancer","volume":"461","author":"Wang","year":"2009","journal-title":"Nature"},{"key":"ref_493","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/ncb2600","article-title":"Multipotent and unipotent progenitors contribute to prostate postnatal development","volume":"14","author":"Ousset","year":"2012","journal-title":"Nat. Cell Biol."},{"key":"ref_494","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/ncb3047","article-title":"Single luminal epithelial progenitors can generate prostate organoids in culture","volume":"16","author":"Chua","year":"2014","journal-title":"Nat. Cell Biol."},{"key":"ref_495","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cell.2014.08.017","article-title":"Identification of multipotent luminal progenitor cells in human prostate organoid cultures","volume":"159","author":"Karthaus","year":"2014","journal-title":"Cell"},{"key":"ref_496","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1038\/ncomms5416","article-title":"Increased Notch signaling inhibits anoikis and stimulates proliferation of prostate luminal epithelial cells","volume":"5","author":"Kwon","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_497","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.molonc.2010.06.009","article-title":"Primitive origins of prostate cancer: In vivo evidence for prostate-regenerating cells and prostate-initiating cells","volume":"4","author":"Goldstein","year":"2010","journal-title":"Mol. Oncol."},{"key":"ref_498","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/stem.2217","article-title":"Stem cell antigen-1 identifies a distinct androgen-independent murine prostatic luminal cell lineage with bipotent potential","volume":"34","author":"Kwon","year":"2016","journal-title":"Stem Cells"},{"key":"ref_499","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1016\/j.celrep.2016.11.010","article-title":"Low CD38 identifies progenitor-like inflammation-associated luminal cells that can initiate human prostate cancer and predict poor outcome","volume":"17","author":"Liu","year":"2016","journal-title":"Cell Rep."},{"key":"ref_500","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40170-018-0186-3","article-title":"CD38 is methylated in prostate cancer and regulates extracellular NAD","volume":"6","author":"Motthedeh","year":"2018","journal-title":"Cancer Metab."},{"key":"ref_501","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1158\/1541-7786.MCR-17-0526","article-title":"CD38 inhibits prostate cancer metabolism and proliferation by reducing cellular NAD+ pools","volume":"16","author":"Chmielewski","year":"2018","journal-title":"Mol. Cancer Res."},{"key":"ref_502","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.stemcr.2017.11.016","article-title":"Histone 2b-GFP label-retaining prostate luminal cells possess progenitor cell properties and are intrinsically resistant to castration","volume":"10","author":"Zhang","year":"2018","journal-title":"Stem Cell Rep."},{"key":"ref_503","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1016\/j.celrep.2018.11.069","article-title":"Single-cell analysis identifies LY6D as marker linking castration-resistant prostate luminal cells to prostate progenitors and cancer","volume":"25","author":"Linn","year":"2018","journal-title":"Cell Rep."},{"key":"ref_504","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/pros.23380","article-title":"A genetic variant near GATA3 implicated in inherited susceptibility and etiology of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS)","volume":"77","author":"Na","year":"2017","journal-title":"Prostate"},{"key":"ref_505","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1038\/s41467-018-06920-9","article-title":"Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA","volume":"9","author":"Gudmundsson","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_506","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1038\/s41598-019-42427-z","article-title":"Heritability and genome-wide association study of benign prostatic hyperplasia (BPH) in the eMERGE network","volume":"9","author":"Hellwege","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_507","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/pros.20599","article-title":"Prostatic stromal cells derived from benign prostatic hyperplasia specimens possess stem cell like property","volume":"67","author":"Lin","year":"2007","journal-title":"Prostate"},{"key":"ref_508","doi-asserted-by":"crossref","first-page":"46710","DOI":"10.18632\/oncotarget.17362","article-title":"Mesenchymal stem cell infiltration during neoplastic transformation of the human prostate","volume":"8","author":"Brennen","year":"2017","journal-title":"Oncotarget"},{"key":"ref_509","doi-asserted-by":"crossref","first-page":"394","DOI":"10.5966\/sctm.2015-0411","article-title":"Aberrant transforming growth factor-\u03b2 activation recruits mesenchymal stem cells during prostatic hyperplasia","volume":"6","author":"Wang","year":"2017","journal-title":"Stem Cells Transl. Med."},{"key":"ref_510","doi-asserted-by":"crossref","unstructured":"Yamamoto, H., Masters, J.R., Dasgupta, P., Chandra, A., Popert, R., Freeman, R., and Ahmed, A. (2012). CD49f is an efficient marker of monolayer and spheroid colony-forming cells of the benign and malignant human prostate. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0046979"},{"key":"ref_511","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1002\/pros.22500","article-title":"Regulation of cell proliferation through a KIT-mediated mechanism in benign prostatic hyperplasia","volume":"72","author":"Imura","year":"2012","journal-title":"Prostate"},{"key":"ref_512","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1101\/gad.196451.112","article-title":"Regulated proteolysis of Trop2 drives epithelail hyperplasia and stem cell self-renewal via beta-catenin signaling","volume":"26","author":"Stoyanova","year":"2012","journal-title":"Genes Dev."},{"key":"ref_513","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41585-018-0087-9","article-title":"Mesenchymal stem cells and the embryonic reawakening theory of BPH","volume":"15","author":"Brennen","year":"2018","journal-title":"Nat. Rev. Urol."},{"key":"ref_514","doi-asserted-by":"crossref","unstructured":"Mei, W., Lin, X., Kapoor, A., Gu, Y., Zhao, K., and Tang, D. (2019). The contributions of prostate cancer stem cells in prostate cancer initiation and metastasis. Cancers, 11.","DOI":"10.3390\/cancers11040434"},{"key":"ref_515","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1158\/0008-5472.CAN-06-4608","article-title":"Prostate cancer cells with stem cell characteristics reconstitute the original tumor in vivo","volume":"67","author":"Gu","year":"2007","journal-title":"Cancer Res."},{"key":"ref_516","doi-asserted-by":"crossref","first-page":"10946","DOI":"10.1158\/0008-5472.CAN-05-2018","article-title":"Prospective identification of tumorigenic prostate cancer stem cells","volume":"65","author":"Collins","year":"2005","journal-title":"Cancer Res."},{"key":"ref_517","first-page":"1683","article-title":"In vitro propagation and characterization of neoplastic stem\/progenitor-like cells from human prostate cancer tissue","volume":"15","author":"Voller","year":"2009","journal-title":"Prostate"},{"key":"ref_518","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.scr.2016.03.003","article-title":"CD133 does not enrich for the stem cell activity in vivo in adult mouse prostates","volume":"16","author":"Wei","year":"2016","journal-title":"Stem Cell Res."},{"key":"ref_519","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s12253-016-0169-z","article-title":"Co-expression of putative cancer stem cell markers CD44 and CD133 in prostate carcinomas","volume":"23","author":"Kalantari","year":"2017","journal-title":"Pathol. Oncol. Res."},{"key":"ref_520","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.canlet.2018.05.014","article-title":"Acquisition of tumorigenic potential and therapeutic resistance in CD133+ subpopulation of prostate cancer cells exhibiting stem cell-like characteristics","volume":"4309","author":"Kanwal","year":"2018","journal-title":"Cancer Lett."},{"key":"ref_521","first-page":"21","article-title":"Molecular analysis of CD133-positive circulating tumor cells from patients with metastatic castration-resistant prostate cancer","volume":"1","author":"Reyes","year":"2015","journal-title":"J. Transl. Sci."},{"key":"ref_522","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/pros.21121","article-title":"Evaluation of the frequency of putative prostate cancer stem cells in primary and metastatic prostate cancer","volume":"70","author":"Eaton","year":"2010","journal-title":"Prostate"},{"key":"ref_523","doi-asserted-by":"crossref","first-page":"5163","DOI":"10.1158\/0008-5472.CAN-09-3806","article-title":"High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer","volume":"70","author":"Cheung","year":"2010","journal-title":"Cancer Res."},{"key":"ref_524","doi-asserted-by":"crossref","first-page":"5361","DOI":"10.1158\/1078-0432.CCR-12-2857","article-title":"Characterization and clinical relevance of ALDH bright populations in prostate cancer","volume":"19","author":"Bubendorf","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_525","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1158\/1078-0432.CCR-15-2956","article-title":"Defining a population of stem-like human prostate cancer cells that can generate and propagate castration-resistant prostate cancer","volume":"22","author":"Chen","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_526","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1158\/0008-5472.CAN-14-1924","article-title":"Aldehyde dehydrogenase is regulated by \u03b2-catenin\/TCF and promotes radioresistance in prostate cancer progenitor cells","volume":"75","author":"Cojoc","year":"2015","journal-title":"Cancer Res."},{"key":"ref_527","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/pros.21473","article-title":"Increased expression of putative cancer stem cell markers in primary prostate cancer is associated with progression of bone metastases","volume":"72","author":"Colombel","year":"2012","journal-title":"Prostate"},{"key":"ref_528","doi-asserted-by":"crossref","unstructured":"Van Leenders, G., Sookhall, R., Tenbel, W., de Ridder, C., Reneman, C., Sacchetti, A., Vissers, K., van Weerden, W., and Jenster, G. (2011). Activation of c-MET induces a stem-like phenotype in human prostate cancer. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0026753"},{"key":"ref_529","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/cas.12104","article-title":"Prostate cancer stem-like cells\/cancer-initiating cells have an autocrine system of hepatocyte growth factor","volume":"104","author":"Nishida","year":"2013","journal-title":"Cancer Sci."},{"key":"ref_530","doi-asserted-by":"crossref","unstructured":"Rybak, A.P., Ingram, A.J., and Tang, D. (2013). Propagation of human prostate cancer stem-like cells occurs through EGFR-mediated ERK activation. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0061716"},{"key":"ref_531","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4161\/cbt.6.5.3996","article-title":"Cancer-stem like cells in human prostate carcinoma cells DU145: The seeds of the cell line?","volume":"6","author":"Wei","year":"2007","journal-title":"Cancer Biol. Ther."},{"key":"ref_532","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.bjc.6604242","article-title":"CD44+CD24-prostate cells are clearly cancer progenitor\/stem cells that provide a model for patients with poor prognosis","volume":"98","author":"Hurt","year":"2008","journal-title":"Br. J. Cancer"},{"key":"ref_533","doi-asserted-by":"crossref","first-page":"6207","DOI":"10.1158\/0008-5472.CAN-05-0592","article-title":"Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic","volume":"65","author":"Patrawala","year":"2005","journal-title":"Cancer Res."},{"key":"ref_534","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/sj.onc.1209327","article-title":"Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tyumorigenic and metastatic progenitor cells","volume":"25","author":"Patrawala","year":"2006","journal-title":"Oncogene"},{"key":"ref_535","doi-asserted-by":"crossref","first-page":"6796","DOI":"10.1158\/0008-5472.CAN-07-0490","article-title":"Hierarchical organization of prostate cancer cells in xenograft tumors: The CD44+apha2beta1+ cell population is enriched in tumor-initiating cells","volume":"67","author":"Patrawala","year":"2007","journal-title":"Cancer Res."},{"key":"ref_536","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cell.2014.08.016","article-title":"Organoid cultures derived from patients with advanced prostate cancer","volume":"159","author":"Gao","year":"2014","journal-title":"Cell"},{"key":"ref_537","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1158\/1078-0432.CCR-13-1105","article-title":"Expression of androgen and estrogen signaling components and stem cell markers to predict cancer progression and cancer-specific survival in patients with metastatic prostate cancer","volume":"20","author":"Fujimura","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_538","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1073\/pnas.0913873107","article-title":"Basal epithelial stem cells are efficient targets for prostate cancer initiation","volume":"107","author":"Lawson","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_539","doi-asserted-by":"crossref","unstructured":"Korsten, H., Ziel-van der Made, A., Ma, X., van der Kwast, T., and Trapman, J. (2009). Accumulating progenitor cells in the luminal epithelial cell layer are candidate tumor initiating cells in a Pten knockout mouse prostate cancer model. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0005662"},{"key":"ref_540","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1172\/JCI58540","article-title":"Nkx3.1 and Myc crossregulate shared target genes in mouse and human prostate tumorigenesis","volume":"122","author":"Anderson","year":"2012","journal-title":"J. Clin. Invest."},{"key":"ref_541","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1158\/1078-0432.CCR-10-2044","article-title":"Transcription-induced DNA double strtand breaks: both oncogenic force and potential therapeutic target?","volume":"17","author":"Haffner","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_542","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.celrep.2014.08.002","article-title":"Luminal cells are favored as the cell of origin for prostate cancer","volume":"8","author":"Wang","year":"2014","journal-title":"Cell Rep."},{"key":"ref_543","first-page":"E592","article-title":"Prostatic inflammation enhances basal-to-luminal differentiation and accelerates initiation of prostate cancer with basal cell origin","volume":"111","author":"Kwon","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_544","doi-asserted-by":"crossref","first-page":"8555","DOI":"10.1158\/0008-5472.CAN-08-4673","article-title":"Lin-Sca-1+CD49fhigh stem\/progenitors are tumor-initiating cells in the Pten-Null prostate cancer model","volume":"69","author":"Mulhollaud","year":"2009","journal-title":"Cancer Res."},{"key":"ref_545","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1126\/science.1189992","article-title":"Identification of a cell of origin for human prostate cancer","volume":"329","author":"Goldstein","year":"2010","journal-title":"Science"},{"key":"ref_546","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/ncb2697","article-title":"Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell-of-origin model for prostate cancer heterogeneity","volume":"15","author":"Wang","year":"2013","journal-title":"Nat. Cell Biol."},{"key":"ref_547","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ccr.2012.01.005","article-title":"Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation","volume":"21","author":"Choi","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_548","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.ajpath.2012.11.025","article-title":"Conditionally ablated PTEN in prostate basal cells promotes basal-to-luminal differentiation and causes invasive prostate cancer in mice","volume":"182","author":"Lu","year":"2013","journal-title":"Am. J. Pathol."},{"key":"ref_549","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1084\/jem.20171207","article-title":"PTEN deletion in luminal cells of mature prostate induces replication stress and senescence","volume":"215","author":"Parisotto","year":"2018","journal-title":"J. Exp. Med."},{"key":"ref_550","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/path.4924","article-title":"A rare castration-resistant progenitor cell population is highly enriched in Pten-null prostate tumors","volume":"243","author":"Boutillon","year":"2017","journal-title":"J. Pathol."},{"key":"ref_551","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1158\/0008-5472.CAN-12-0228","article-title":"Collaboration of KRas and androgen receptor signaling stimulates EZH2 expression and tumor propagating cells in prostate cancer","volume":"72","author":"Cai","year":"2012","journal-title":"Cancer Res."},{"key":"ref_552","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/PAT.0000000000000325","article-title":"Cancer stem cell markers in prostate cancer: An immunohistochemical study of ALDH1, SOX2 and EZH2","volume":"47","author":"Matsika","year":"2015","journal-title":"Pathology"},{"key":"ref_553","first-page":"7072","article-title":"TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup","volume":"23","author":"Sweeney","year":"2017","journal-title":"Cancer Res."},{"key":"ref_554","doi-asserted-by":"crossref","unstructured":"Gorodetska, I., Lukiyanchulk, V., Peitzsch, C., Kozetska, I., and Dubrovska, A. (2019). BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype. Int. J. Cancer.","DOI":"10.1002\/ijc.32323"},{"key":"ref_555","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1227604","article-title":"EZH2 oncogenic activity in castration-resistant prostate cancer cells is polycomb-independent","volume":"338","author":"Xu","year":"2012","journal-title":"Science"},{"key":"ref_556","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1016\/j.celrep.2018.11.035","article-title":"Polycomb-and methylation-indepoendent roles of EZH2 as a transcription activator","volume":"25","author":"Kim","year":"2018","journal-title":"Cell Rep."},{"key":"ref_557","doi-asserted-by":"crossref","first-page":"9911","DOI":"10.1074\/jbc.RA119.008152","article-title":"Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide-resistance in castration-resistance prostate cancer","volume":"294","author":"Bai","year":"2019","journal-title":"J. Biol. Chem."},{"key":"ref_558","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1158\/0008-5472.CAN-16-1949","article-title":"Polycomb-mediated disruption of an androgen receptor feedback loop drives castration-resistant prostate cancer","volume":"77","author":"Fong","year":"2017","journal-title":"Cancer Res."},{"key":"ref_559","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm.4036","article-title":"Targeting EZH2 in cancer","volume":"22","author":"Kim","year":"2016","journal-title":"Nat. Med."},{"key":"ref_560","doi-asserted-by":"crossref","unstructured":"Taplin, M.E., Hussain, A., Shore, N.D., Bradley, B., Trojer, P., and Lebedinsky, C. (2018). A phase 1b\/2 of CPI-1205, a small molecule inhibitor of EZH2, combined with enzalutamide (E) or abiraterone\/rpednisone (A\/P) in patients with metastatic castration resistant prostate cancer (mCRPC). J. Clin. Oncol., 36.","DOI":"10.1200\/JCO.2018.36.6_suppl.TPS398"},{"key":"ref_561","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms1159","article-title":"Tumor-initiating stem-like cells in human prostate cancer exhibit increased NF-kB signaling","volume":"2","author":"Rajasekhar","year":"2011","journal-title":"Nat. Commun"},{"key":"ref_562","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1158\/1541-7786.MCR-12-0468","article-title":"Genetic ablation of the teraspanin CD151 reduces spontaneous metastatic spread of prostate cancer in the TRAMP model","volume":"11","author":"Copeland","year":"2013","journal-title":"Mol. Cancer Res."},{"key":"ref_563","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/0008-5472.CAN-13-1296","article-title":"ALCAM\/CD166 is a TGF-\u03b2-responsive marker and functional regulator of prostate cancer metastasis to bone","volume":"74","author":"Hansen","year":"2014","journal-title":"Cancer Res."},{"key":"ref_564","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.stem.2012.03.009","article-title":"The PSA-\/lo prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration","volume":"10","author":"Qin","year":"2012","journal-title":"Cell Stem Cell"},{"key":"ref_565","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nm.2284","article-title":"The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44","volume":"17","author":"Liu","year":"2011","journal-title":"Nat. Med."},{"key":"ref_566","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.celrep.2014.02.023","article-title":"miR-34 cooperates with p53 in suppression of prostate cancer by point regulation of stem cells compartment","volume":"6","author":"Cheng","year":"2014","journal-title":"Cell Rep."},{"key":"ref_567","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/s41419-018-0541-x","article-title":"p53-dependent CD51 expression contributes to characteristics of cancer stem cells in prostate cancer","volume":"9","author":"Sui","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_568","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1158\/0008-5472.CAN-10-3320","article-title":"HIF induces human embryonic stem cell markers in cancer cells","volume":"71","author":"Mathieu","year":"2011","journal-title":"Cancer Res."},{"key":"ref_569","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/jmcb\/mjr002","article-title":"SOX2 promotes tumorigenesis and increases the anti-apoptotic property of human prostate cancer cell","volume":"3","author":"Jia","year":"2011","journal-title":"J. Mol. Cell. Biol."},{"key":"ref_570","doi-asserted-by":"crossref","first-page":"3833","DOI":"10.1038\/onc.2011.114","article-title":"NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation","volume":"30","author":"Jeter","year":"2011","journal-title":"Oncogene"},{"key":"ref_571","doi-asserted-by":"crossref","first-page":"16041","DOI":"10.1038\/celldisc.2016.41","article-title":"NANOG reprograms prostate cancer cells to castration resistance via dynamically repressing and engaging the AR\/FOXA1 signaling axis","volume":"2","author":"Jeter","year":"2016","journal-title":"Cell Discov."},{"key":"ref_572","doi-asserted-by":"crossref","first-page":"4412","DOI":"10.1038\/s41388-019-0712-y","article-title":"The induction of core pluripotency master regulators in cancers defines poor clinical outcomes and treatment resistance","volume":"38","author":"Hepburn","year":"2019","journal-title":"Oncogene"},{"key":"ref_573","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1172\/JCI66666","article-title":"ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer","volume":"123","author":"Cai","year":"2013","journal-title":"J. Clin. Invest."},{"key":"ref_574","doi-asserted-by":"crossref","unstructured":"Khurana, N., and Sikka, S.C. (2019). Interplay between SOX9, Wnt\/\u03b2-catenin and androgen receptor signaling in castration-resistant prostate cancer. Mol. Sci., 20.","DOI":"10.3390\/ijms20092066"},{"key":"ref_575","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1002\/pros.22527","article-title":"Long-term recovery of irradiated prostate cancer increases cancer stem cells","volume":"72","author":"Cho","year":"2012","journal-title":"Prostate"},{"key":"ref_576","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/cdd.2014.97","article-title":"Radiotherapy-induced plasticity of prostate cancer mobilizes stem-like non-adherent, Erk signaling-dependent cells","volume":"22","author":"Kyjacova","year":"2015","journal-title":"Cell Death Diff."},{"key":"ref_577","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/mc.22913","article-title":"SMCA1 is associated with radioresistance in prostate cancer and acts by regulating epithelial-mesenchymal transition and cancer stem-like properties","volume":"19","author":"Yadav","year":"2019","journal-title":"Mol. Carcinog."},{"key":"ref_578","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ccr.2012.07.016","article-title":"Suppression of acquired docetaxel resistance in prostate cancer through depletion of Notch-and hedgehog-dependent tumor-initiating cells","volume":"22","author":"Vidal","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_579","doi-asserted-by":"crossref","unstructured":"Singh, S., Chitkara, D., Mehzarin, R., Behrman, S.W., Wake, R.W., and Mahato, R.I. (2012). Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0040021"},{"key":"ref_580","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/pros.22830","article-title":"The role of the SHH gene in prostate cancer cell resistance to paclitaxel","volume":"74","author":"Statkiewicz","year":"2014","journal-title":"Prostate"},{"key":"ref_581","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s11010-014-2069-4","article-title":"NOTCH1 signaling promotes chemoresistance via regulainting ABCC1 expression in prostate cancer stem cells","volume":"393","author":"Liu","year":"2014","journal-title":"Mol. Cell. Biochem."},{"key":"ref_582","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1097\/CAD.0000000000000659","article-title":"Reversal docetaxel resistance in prostate cancer by Notch signaling inhibition","volume":"29","author":"Qiu","year":"2018","journal-title":"Anticancer Drugs"},{"key":"ref_583","doi-asserted-by":"crossref","unstructured":"Siddique, H.R., Parray, A., Tarapore, R., Wang, L., Mukhtar, H., Karnes, R.J., Deng, Y., Kornety, B.R., and Saleem, M. (2013). BMI1 polycomb group protein acts as a master switch for groth and death of tumor cells: Regulates TCF4-transcriptional factor-induced BCL2 signaling. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0060664"},{"key":"ref_584","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1080\/15384101.2017.1312237","article-title":"Activation of Notch pathway is linked with epithelial-mesenchymal transition in prostate cancer","volume":"16","author":"Zhang","year":"2017","journal-title":"Cell Cycle"},{"key":"ref_585","doi-asserted-by":"crossref","first-page":"6744","DOI":"10.1158\/1078-0432.CCR-17-0913","article-title":"Numb-\/low enriches a castration-resistant prostate cancer subpopulation associated with enhanced Notch and Hedgehog signaling","volume":"23","author":"Guo","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_586","doi-asserted-by":"crossref","first-page":"8543","DOI":"10.1074\/jbc.RA118.006983","article-title":"NOTCH signaling is activated in and contributes to resistance in enzalutamide-resistant prostate cancer cells","volume":"294","author":"Farah","year":"2019","journal-title":"J. Biol. Chem."},{"key":"ref_587","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nature08782","article-title":"B-cell-derived lymphotoxin promotes castration-resistant prostate cancer","volume":"454","author":"Ammirante","year":"2010","journal-title":"Nature"},{"key":"ref_588","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1101\/gad.220202.113","article-title":"An IKK\u03b1-E2F1-BMI1 cascade activated by infiltrating B cells controls prostate regeneration and tumor recurrence","volume":"27","author":"Ammirante","year":"2013","journal-title":"Genes Dev."},{"key":"ref_589","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1158\/0008-5472.CAN-14-0404","article-title":"miRNa-128 suppresses prostate cancer by inhibiting BMI-1 to inhibit tumor-initiasting cells","volume":"74","author":"Jin","year":"2014","journal-title":"Cancer Res."},{"key":"ref_590","doi-asserted-by":"crossref","first-page":"6176","DOI":"10.1158\/1078-0432.CCR-15-3107","article-title":"BMI-1 targeting interferes with patient-derived tumor-initiating cell survival and tumor growth in prostate cancer","volume":"22","author":"Bansal","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_591","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/s41467-018-02863-3","article-title":"BMI1 regulates androgen receptor in prostate cancer independently of the polycomb repressive complex 1","volume":"9","author":"Zhu","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_592","doi-asserted-by":"crossref","first-page":"12943","DOI":"10.1038\/ncomms12943","article-title":"Bmi1 marks distinct castration-resistant luminal progenitor cells competent for prostate regeneration and tumor initiation","volume":"7","author":"Yoo","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_593","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/jnci\/djy142","article-title":"The role of castration-resistant Bmi1+Sox2+ cells in driving recurrence in prostate cancer","volume":"111","author":"Yoo","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_594","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.1158\/0008-5472.CAN-13-0874","article-title":"JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells","volume":"73","author":"Kroon","year":"2013","journal-title":"Cancer Res."},{"key":"ref_595","doi-asserted-by":"crossref","first-page":"7090","DOI":"10.1158\/0008-5472.CAN-13-1560","article-title":"Generation of prostate tumor-initiating cells is associated with elevation of reactive oxygen species and IL-6\/STAT3 signaling","volume":"73","author":"Qu","year":"2013","journal-title":"Cancer Res."},{"key":"ref_596","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/0008-5472.CAN-13-0594","article-title":"Loss of androgen receptor expression promotes a stem-like cell pgenotype in prostate cancer through STAT3 signaling","volume":"74","author":"Schoereder","year":"2014","journal-title":"Cancer Res."},{"key":"ref_597","doi-asserted-by":"crossref","first-page":"8416","DOI":"10.18632\/oncotarget.2314","article-title":"Inhibition of STAT3 signaling targets both tumor-initiating and differentiated cell populations in prostate cancer","volume":"5","author":"Han","year":"2014","journal-title":"Oncotarget"},{"key":"ref_598","doi-asserted-by":"crossref","first-page":"4612","DOI":"10.1158\/1078-0432.CCR-18-0461","article-title":"Reciprocal network between cancer stem-like cells and macrophages facilitates the progression and androgen deprivation therapy resistance of prostate cancer","volume":"24","author":"Huang","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_599","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1172\/JCI86505","article-title":"MicroRNA-424 impairs ubiquitination to activate STAT3 and promote prostate tumor progression","volume":"126","author":"Dallavalle","year":"2016","journal-title":"J. Clin. Invest."},{"key":"ref_600","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/pros.23787","article-title":"Expression of tSTAT3, pSTAT727 and pSTAT705 in the epithelial cells of hormone-na\u00efve prostate cancer","volume":"79","author":"Krzyzanowska","year":"2019","journal-title":"Prostate"},{"key":"ref_601","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.eururo.2016.06.018","article-title":"Expression of STAT3 in prostate cancer metastases","volume":"71","author":"Marginean","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_602","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mce.2017.03.012","article-title":"Interleukin-6 and prostate cancer: Current developments and unsolved questions","volume":"462","author":"Culig","year":"2018","journal-title":"Mol. Cell Endrocrinol."},{"key":"ref_603","first-page":"682","article-title":"\u03b24 integrin signaling induces expansion of prostate tumor progenitors","volume":"123","author":"Yoshioka","year":"2013","journal-title":"J. Clin. Invest."},{"key":"ref_604","first-page":"178","article-title":"Glycogen synthase kinase 3 and prostate cancer: An update","volume":"23","author":"Hu","year":"2017","journal-title":"Zhongua Nan Ke Xue"},{"key":"ref_605","doi-asserted-by":"crossref","first-page":"8986","DOI":"10.18632\/oncotarget.1510","article-title":"Glycogen synthase kinase-3beta inhibition depletes the population of prostate cancer stem\/progenitor-like cells and attenuates metastatic growth","volume":"15","author":"Kroon","year":"2014","journal-title":"Oncotarget"},{"key":"ref_606","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.eururo.2016.10.013","article-title":"Translating a prognostic DNA genomic classifier into the clinic: retrospective validation in 563 localized prostate tumors","volume":"72","author":"Lalonde","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_607","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1158\/1078-0432.CCR-11-2711","article-title":"Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer","volume":"18","author":"Milosevic","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_608","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1158\/1541-7786.MCR-14-0153-T","article-title":"HIF-1 alpha regulates mTOR signaling and viability of prostate cancer stem cells","volume":"13","author":"Marhold","year":"2015","journal-title":"Mol Cancer Res"},{"key":"ref_609","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.stem.2019.03.010","article-title":"Spatially restricted stromal Wnt signaling restrains prostate epithelial progenitor growth through direct and indirect mechanisms","volume":"24","author":"Wei","year":"2019","journal-title":"Cell Stem Cell"},{"key":"ref_610","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/nrurol.2017.144","article-title":"WNT signaling in prostate cancer","volume":"14","author":"Kypta","year":"2017","journal-title":"Nat. Rev. Urol."},{"key":"ref_611","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1158\/1078-0432.CCR-15-0190","article-title":"Targeting cancer stem cells in catsration-resistant prostate cancer","volume":"22","author":"Yun","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_612","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1158\/0008-5472.CAN-17-3006","article-title":"Inhibition of the Wnt\/\u03b2-catenin pathway overcomes resistance to Enzalutamide in castration-resistant prostate cancer","volume":"78","author":"Zhang","year":"2018","journal-title":"Cancer Res."},{"key":"ref_613","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.ebiom.2019.03.032","article-title":"Cell division cycle 20 (CDc20) drives prostate cancer progression via stabilization of \u03b2-catenin in cancer stem-like cells","volume":"42","author":"Zhang","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_614","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.ccell.2019.03.001","article-title":"CHD1 loss alters AR binding at lineage-specific enhnacers and modulates distinct transcriptional programs to drive prostate tumorigenesis","volume":"35","author":"Augello","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_615","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nprot.2011.317","article-title":"Purification and direct transformation of epithelial progenitor cells from primary human prostate","volume":"6","author":"Goldstein","year":"2011","journal-title":"Nat. Protoc."},{"key":"ref_616","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/nprot.2010.11","article-title":"Isolation, cultivation and characterization of adult murine prostate stem cells","volume":"5","author":"Lukacs","year":"2010","journal-title":"Nat. Protoc."},{"key":"ref_617","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.diff.2014.01.003","article-title":"Cross-species stromal signaling programs human embryonic stem cell differentiation","volume":"87","author":"Taylor","year":"2014","journal-title":"Differentiation"},{"key":"ref_618","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1002\/stem.668","article-title":"Brief report: A bioassay to identify primary human prostate cancer repopulating cells","volume":"29","author":"Toivanen","year":"2011","journal-title":"Stem Cells"},{"key":"ref_619","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/nprot.2013.043","article-title":"A preclinical xenograft model of prostate cancer using human tumors","volume":"8","author":"Lawrence","year":"2013","journal-title":"Nat. Protoc."},{"key":"ref_620","doi-asserted-by":"crossref","unstructured":"Namekawa, T., Ikeda, K., Horie-Inoue, K., and Inoue, S. (2019). Application of prostate cancer models for preclinical study: Advantages and limitations of cell lines, patient-derived xenografts, and three-dimensional culture of patient-derived cells. Cells, 8.","DOI":"10.3390\/cells8010074"},{"key":"ref_621","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s12672-016-0266-1","article-title":"Patient-derived prostate cancer: From basic science to the clinic","volume":"7","author":"Risbridger","year":"2016","journal-title":"Horm. Cancer"},{"key":"ref_622","doi-asserted-by":"crossref","first-page":"ao30356","DOI":"10.1101\/cshperspect.a030536","article-title":"Preclinical models of prostate cancer: Patient-derived xenografts, organoids, and other explant models","volume":"8","author":"Risbridger","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_623","doi-asserted-by":"crossref","first-page":"187ra71","DOI":"10.1126\/scitranslmed.3005688","article-title":"A preclinical xenograft model identifies castration-tolerant cancer-repopulating cells in localized prostate tumors","volume":"5","author":"Toivanen","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_624","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/jmcb\/mjs042","article-title":"New therapy targeting differential androgen receptor signaling in prostate cancer stem\/progenitor vs. non-stem\/progenitor cells","volume":"5","author":"Lee","year":"2013","journal-title":"J. Mol. Cell. Biol."},{"key":"ref_625","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.eururo.2018.06.020","article-title":"Patient-derived models of Abiraterone-and Enzalutamide-resistant prostate cancer reveal sensitivity to ribosome-directed therapy","volume":"74","author":"Lawrence","year":"2018","journal-title":"Eur. Urol."},{"key":"ref_626","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/bju.14043","article-title":"Intraductal carcinoma of the prostate can evade androgen deprivation, with emergence of castrate-tolerant cells","volume":"12","author":"Porder","year":"2018","journal-title":"BJU Int."},{"key":"ref_627","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1002\/pros.22685","article-title":"Enrichment of putative prostate cancer stem cells after androgen deprivation: Upregulation of pluripotency trasactivators concurs with resistance to androgen deprivation in LNCaP cell lines","volume":"73","author":"Seiler","year":"2013","journal-title":"Prostate"},{"key":"ref_628","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nrclinonc.2013.107","article-title":"Genetics: ZBTB7A suppresses castration-resistant prostate cancer","volume":"10","author":"Razzak","year":"2013","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_629","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/ng.2650","article-title":"A co-clinical approach identifies mechansims and potential therapies for androgen deprivation resistance in prostate cancer","volume":"45","author":"Lunardi","year":"2013","journal-title":"Nature Genet."},{"key":"ref_630","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1158\/1078-0432.CCR-14-1108","article-title":"Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cance cell growth","volume":"21","author":"Yamamoto","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_631","doi-asserted-by":"crossref","first-page":"5731","DOI":"10.1158\/0008-5472.CAN-18-0941","article-title":"Epigenetic reprogramming with antisence oligonucleotides enhances the effectiveness of androgen receptor inhibition in catsrtaion-resistant prostate cancer","volume":"78","author":"Xino","year":"2018","journal-title":"Cancer Res."},{"key":"ref_632","first-page":"2579","article-title":"First-in-human phase I study of ENZ-4176, a locked nucleic acid antisense oligonucleotide (LNA-ASO) to androgen receptor (AR) mRNA in patients with castration-resistant prostate cancer (CRPC)","volume":"109","author":"Bianchini","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_633","doi-asserted-by":"crossref","unstructured":"Mohammed, O.S., Nyquist, M.D., Schweitzer, M.T., Balk, S.P., Corey, E., Plymate, S., Nelson, P.S., and Mostaghel, E.A. (2017). Supraphysiological testaosterone therapy in the treatment of prostate cancer: Models, mechanism and questions. Cancers, 9.","DOI":"10.3390\/cancers9120166"},{"key":"ref_634","first-page":"269ra2","article-title":"Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer. Results from a pilot clinical study","volume":"7","author":"Schweitzer","year":"2015","journal-title":"Sci.Transl. Med."},{"key":"ref_635","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S1470-2045(17)30906-3","article-title":"Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer fater progression on enzalutamide: An open-label, phase 2, multicohort study","volume":"19","author":"Teplin","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_636","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1200\/EDBK_239187","article-title":"The evolving role of prostate-specific membrane antigen-based diagnostics and therapeutics in prostate cancer","volume":"39","author":"Dorff","year":"2019","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_637","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","article-title":"[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): A single-centre, single-arm, phase 2 study","volume":"19","author":"Hofman","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_638","doi-asserted-by":"crossref","unstructured":"Targeted Alpha Therapy Working Group, Parker, C., Lwington, V., Shore, N., Kratochwil, C., Levy, M., Linden, O., Noordzij, W., Park, J., and Saad, F. (2018). Targeted alpha therapy, an emerging class of cancer agents: A review. Jama Oncol., 4, 1765\u20131772.","DOI":"10.1001\/jamaoncol.2018.4044"},{"key":"ref_639","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1470-2045(18)30757-5","article-title":"Short-term androgen suppression and radiotherapy versus intermediate-arm androgen suppression and radiotherapy, with or without zolendronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10 year results from a randomized, phase 3, factorial trial","volume":"20","author":"Denham","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_640","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/S1470-2045(18)30528-X","article-title":"Sequence of hormonal therapy and radiotherapy field size in unfavourable, localized prostate cancer (NRG\/RTOG 9413): Long-term results of a randomized, phase 3 trial","volume":"19","author":"Roach","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_641","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1001\/jamaoncol.2018.4836","article-title":"Surgery vs. radiotherapy in the management of biopsy Gleason score 9-10 prostate cancer and the risk of mortality","volume":"5","author":"Tiki","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_642","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/jamaoncol.2018.5801","article-title":"Analysis of prevalence of microsatellite instabilities of prostate cancer and response to immune checkpoint blockade","volume":"5","author":"Abida","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_643","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.cell.2013.11.012","article-title":"Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade","volume":"155","author":"Arora","year":"2013","journal-title":"Cell."},{"key":"ref_644","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s42003-018-0128-1","article-title":"Frequent mutation of the FOXA1 untranslated region in prostate cancer","volume":"1","author":"Annala","year":"2018","journal-title":"Commun. Biol."},{"key":"ref_645","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/nature10006","article-title":"Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA","volume":"474","author":"Wang","year":"2011","journal-title":"Nature"},{"key":"ref_646","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.gendis.2015.01.003","article-title":"Current perspectives on FOXA1 regulation of androgen receptor signaling and prostate cancer","volume":"2","author":"Yang","year":"2015","journal-title":"Genes Dis."},{"key":"ref_647","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1038\/ncomms4972","article-title":"Coopereativity and equilibrium with FOXA1 define the androgen receptor transcriptional program","volume":"5","author":"Jin","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_648","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1158\/0008-5472.CAN-12-3468","article-title":"Androgen receptor-independent function of FOXA1 in prostate cancer metastasis","volume":"73","author":"Jin","year":"2013","journal-title":"Cancer Res."},{"key":"ref_649","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1038\/onc.2017.50","article-title":"FOXA1 inhibits prostate cancer neuroendocrine differentiation","volume":"36","author":"Kim","year":"2017","journal-title":"Oncogene"},{"key":"ref_650","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1172\/JCI122367","article-title":"Taregting FOXA1-mediated repression of TGF-\u03b2 signaling suppresses castration-resistant prostate cancer progression","volume":"129","author":"Song","year":"2019","journal-title":"J. Clin. Invest."},{"key":"ref_651","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1038\/onc.2015.496","article-title":"FOXA1 cats upstream of GATA2 and AR in hormonal regulation of gene expression","volume":"35","author":"Zhao","year":"2016","journal-title":"Oncogene"},{"key":"ref_652","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrurol.2016.225","article-title":"The role of GATA2 in lethal cancer aggressiveness","volume":"14","author":"Hoshida","year":"2017","journal-title":"Nat. Rev. Urol."},{"key":"ref_653","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1006\/bbrc.2000.2784","article-title":"A novel cell adhesion inhibitor, K-7174, reduces the endothelial VCAM-1 induction by inflammatory cytokines, acting through the regulation of GATA","volume":"272","author":"Umetani","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_654","doi-asserted-by":"crossref","first-page":"18261","DOI":"10.1073\/pnas.1421415111","article-title":"GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex","volume":"111","author":"He","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_655","doi-asserted-by":"crossref","first-page":"29782","DOI":"10.18632\/oncotarget.4927","article-title":"FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer","volume":"6","author":"Jones","year":"2015","journal-title":"Oncotarget"},{"key":"ref_656","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nature24028","article-title":"Discovery of a selective catalytic p300\/CBP inhibitor that targets lineage-specific tumours","volume":"550","author":"Lasko","year":"2017","journal-title":"Nature"},{"key":"ref_657","doi-asserted-by":"crossref","first-page":"5564","DOI":"10.1158\/0008-5472.CAN-17-0314","article-title":"Therapeutic targeting of the CBP\/p300 bromodomain blocks the growth of castration-resistant prostate cancer","volume":"77","author":"Jin","year":"2017","journal-title":"Cancer Res."},{"key":"ref_658","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1158\/1078-0432.CCR-17-3571","article-title":"Targeting bromodomain and extra-terminal (BET) family proteins in castration-resistant prostate cancer (CRPC)","volume":"24","author":"Welti","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_659","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1016\/j.celrep.2017.05.049","article-title":"Androgen receptor deregulation drives bromodomain -mediated chromatin alterations in prostate cancer","volume":"19","author":"Urbanucci","year":"2017","journal-title":"Cell Rep."},{"key":"ref_660","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1158\/1541-7786.MCR-15-0472","article-title":"BET bromodomain inhibitors enhance efficacy and disrupt resistance to AR antagonists in the treatment of prostate cancer","volume":"14","author":"Asangani","year":"2016","journal-title":"Mol. Cancer Res."},{"key":"ref_661","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.2018.78.2292","article-title":"Phase Ib trial with birabresib, a small-molecule inhibitor of bromodomain and extraterminal proteins, in patients with selected advanced solid tumors","volume":"36","author":"Lewin","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_662","doi-asserted-by":"crossref","unstructured":"Aggarwal, R., Abida, W., Schweizer, M., Pantuck, A., Nanus, D., Heath, E., Lakhotia, S., Hansen, H.C., Silverman, H., and Bauman, L. (April, January 29). CTo95: A phase Ib\/IIa study of the BET bromodomain inhibitor ZEN-3694 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC). Proceedings of the AACR Meeting 2019, Atlanta, GA, USA.","DOI":"10.1158\/1538-7445.SABCS18-CT095"},{"key":"ref_663","doi-asserted-by":"crossref","first-page":"333ra49","DOI":"10.1126\/scitranslmed.aac5954","article-title":"Individualizing liver transplant immunosuppression using a phenotypic personalized medicine platform","volume":"8","author":"Zarrinpar","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_664","doi-asserted-by":"crossref","first-page":"1800104","DOI":"10.1002\/adtp.201800104","article-title":"Modulating BET bromodomain inhibitor ZEN-3694 and Enzalutamide combination dosing in a metastatic prostate cancer patient using CURATE.A1, an artificial intelligence platform","volume":"1","author":"Pantuck","year":"2018","journal-title":"Adv. Ther."},{"key":"ref_665","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1016\/j.celrep.2018.02.011","article-title":"Resistance to BET inhibitor leads to alternative therapeutic vulnerabilities in castration-resistant prostate cancer","volume":"22","author":"Pawar","year":"2018","journal-title":"Cell. Rep."},{"key":"ref_666","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0093-7754(03)00346-4","article-title":"HSP90 as a therapeutic target in propstate cancer","volume":"30","author":"Solit","year":"2003","journal-title":"Sem. Oncol."},{"key":"ref_667","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1158\/1535-7163.MCT-16-0241","article-title":"Cotargeting HSP90 and its client proteins for treatment of prostate cancer","volume":"15","author":"Chen","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_668","doi-asserted-by":"crossref","first-page":"8699","DOI":"10.1074\/jbc.RA119.007420","article-title":"Phosphorylation of HSP90 by protein kinase A is essential for the nuclear translocation of androgen receptor","volume":"294","author":"Dagar","year":"2019","journal-title":"J. Biol. Chem."},{"key":"ref_669","doi-asserted-by":"crossref","first-page":"17239","DOI":"10.1038\/s41598-018-35417-0","article-title":"High-throughput screens identifiey HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer","volume":"8","author":"Jansson","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_670","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s10637-015-0307-6","article-title":"A phase II trial of ganetespib, a heat shock protein 90 (Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trial consortium (PCCTC) study","volume":"34","author":"Thakur","year":"2016","journal-title":"Invest. New Drugs"},{"key":"ref_671","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1158\/0008-5472.CAN-15-2186","article-title":"Second-generation SHP90 inhibitor Onalespib blocks mRNA spilicing of androgen receptor varian 7 in prostate cancer cells","volume":"76","author":"Ferraldeschi","year":"2016","journal-title":"Cancer Res."},{"key":"ref_672","doi-asserted-by":"crossref","unstructured":"Slovin, S.F., Hussain, S., Saad, F., Garcia, J.A., Picus, J., Ferraldeschi, R., Crespo, M., Flohr, P.R., Riisnaes, R., and Lin, C. (2019). Pharmacodynamic and clinical results from a phase 1\/2 study of the HSP90 inhibitor Onalespib in combination with Abirateronew acetate in prostate cancer. Clin. Cancer Res.","DOI":"10.1158\/1078-0432.CCR-18-3212"},{"key":"ref_673","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/cncr.21261","article-title":"MDM2 as a predictor of prostate carcinoma outcome: An analysis of Radiation Therapy Oncology Group Protocol 8610","volume":"104","author":"Khor","year":"2005","journal-title":"Cancer"},{"key":"ref_674","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1200\/JCO.2008.19.8267","article-title":"MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 982-02","volume":"27","author":"Khor","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_675","first-page":"1125","article-title":"Constant degradation of the androgen receptor by MDM2 conserves prostate cancer stem cell integrity","volume":"79","author":"Giridhar","year":"2019","journal-title":"Cancer Res."},{"key":"ref_676","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.neo.2016.01.006","article-title":"MDM2 inhibition sensitizes prostate cancer cells ablalation and radiotherapy in a p53-dependent manner","volume":"18","author":"Feng","year":"2016","journal-title":"Neoplasia"},{"key":"ref_677","doi-asserted-by":"crossref","unstructured":"Roxburgh, P., Currie, D., Morrisonm, P., Kelly, C., Thomson, F., McCormick, C., Bilsiand, A., Jones, R.H., Quinton, A., and McCartney, E. (April, January 29). Abstract CT027: Safety, pharmacokinetics (PK) & pharmacodynamics (PD) of idasanutlin (idasa), combined with abiraterone (abi)\/prednisone (pred) or enzalutamide (enza) in castrate resistant prostate cancer (CRPC). Proceedings of the AACR Meeting 2019, Atlanta, GA, USA.","DOI":"10.1158\/1538-7445.AM2018-CT027"},{"key":"ref_678","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nrurol.2018.22","article-title":"Cellular plasticity and the neuroendocrine phenotype in prostate cancer","volume":"15","author":"Davies","year":"2018","journal-title":"Nat. Rev. Urol."},{"key":"ref_679","doi-asserted-by":"crossref","first-page":"eaav0891","DOI":"10.1126\/scitranslmed.aav0891","article-title":"Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer","volume":"11","author":"Puca","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_680","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/2159-8290.CD-11-0130","article-title":"Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets","volume":"1","author":"Beltran","year":"2011","journal-title":"Cancer Discov."},{"key":"ref_681","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1593\/neo.121550","article-title":"Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer","volume":"15","author":"Mosquerra","year":"2013","journal-title":"Neoplasia"},{"key":"ref_682","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ccell.2016.03.001","article-title":"N-Myc drives neuroendocrine prostate cancer initiated from human prostate epithelial cells","volume":"29","author":"Lee","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_683","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1158\/1078-0432.CCR-17-1872","article-title":"Targeting the MYCN-PARP-DNA damage response pathway in neuroendocrine prostate cancer","volume":"24","author":"Zhang","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_684","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12943-019-0941-2","article-title":"N-Myc promotes therapeutic resistance development of neuroendocrine development of neuroendocrine prostate cancer by differentially regulating miR-421\/ATM pathway","volume":"18","author":"Yin","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_685","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1001\/jamaoncol.2016.0494","article-title":"Genomic alterations in cell-free DNA and ERnzalutamide resistance in castration-resistant prostate cancer","volume":"2","author":"Wyatt","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_686","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1158\/1078-0432.CCR-19-0404","article-title":"Novel RB1-loss transcriptomic signature is associated with poor clinical outcomes across cancer types","volume":"25","author":"Chen","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_687","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41568-018-0008-5","article-title":"Non-canonical functions of the RB protein in cancer","volume":"18","author":"Dick","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_688","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.celrep.2016.09.064","article-title":"Androgen receptor tumor suppressor function is mediated by recruitment of retinoblastoma protein","volume":"17","author":"Gao","year":"2016","journal-title":"Cell Rep."},{"key":"ref_689","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1158\/1078-0432.CCR-19-1292","article-title":"Retinoblastoma loss in cancer: Casting a wider net","volume":"25","author":"Choudhury","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_690","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41586-019-1172-9","article-title":"RB constrains lineage fidelity and multiple stages of tumour progression and metastasis","volume":"569","author":"Walter","year":"2019","journal-title":"Nature"},{"key":"ref_691","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1158\/2159-8290.CD-18-0389","article-title":"Cells lacking the RB1 tumor suppressor gene are hyperdependent in Aurora B kinase for survival","volume":"9","author":"Oser","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_692","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1158\/2159-8290.CD-18-0469","article-title":"Aurora A kinase inhibition is synthetic lethal with loss of the RB1 tumor suppressor gene","volume":"9","author":"Gong","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_693","doi-asserted-by":"crossref","first-page":"E11894","DOI":"10.1073\/pnas.1811158115","article-title":"Quantitative conformational profiling of kinase inhibitors reveals origins of selectivity for Aurora kinase activation states","volume":"115","author":"Lake","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_694","doi-asserted-by":"crossref","unstructured":"Bleijs, M., van de Watering, M., Clevers, H., and Drost, J. (2019). Xenograft and organoid model systems in cancer research. EMBO J., e101654.","DOI":"10.15252\/embj.2019101654"},{"key":"ref_695","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1158\/0008-5472.CAN-13-2921-T","article-title":"High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development","volume":"74","author":"Lin","year":"2014","journal-title":"Cancer Res."},{"key":"ref_696","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/pros.23313","article-title":"Lucap prostate cancer patient-derived xenografts reflect the molecular heterogeneity of advanced disease and serve as models for evaluating cancer therapeutics","volume":"77","author":"Nguyen","year":"2017","journal-title":"Prostate"},{"key":"ref_697","doi-asserted-by":"crossref","first-page":"42795","DOI":"10.1038\/srep42795","article-title":"REST is a crucial regulator for acquiring EMT-like and stemness phenotypes in hormone-refractory prostate cancer","volume":"7","author":"Chang","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_698","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1158\/1078-0432.CCR-18-0729","article-title":"Proteogenomic characterization of patient-derived xenografts highlights the role of REWST in neuroendocrine differentiation of castration-resistant prostate cancer","volume":"25","author":"Bermann","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_699","doi-asserted-by":"crossref","first-page":"17535","DOI":"10.1038\/s41598-018-35695-8","article-title":"Development and characterization of a spontaneously metastatic patient-derived xenograft model of human prostate cancer","volume":"8","author":"Lange","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_700","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/pros.23701","article-title":"Movember gap1 pdx project: An international collection of serially transplantable cancer patient-derived xenograft (pdx) models","volume":"78","author":"Navone","year":"2018","journal-title":"Prostate"},{"key":"ref_701","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/1878-0261.12354","article-title":"A patient-derived explant (PDE) model of hormone-dependent cancer","volume":"12","author":"Centenera","year":"2018","journal-title":"Mol. Oncol."},{"key":"ref_702","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1073\/pnas.1603645113","article-title":"Prostate epithelial cell of origin determines cancer differentiation state in an organoid transformation assay","volume":"113","author":"Park","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_703","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1038\/s41467-018-04495-z","article-title":"Patient derived organoids to model rare prostate cancer phenotypes","volume":"9","author":"Puca","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_704","first-page":"127961","article-title":"N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer","volume":"130","author":"Berger","year":"2019","journal-title":"J. Clin. Invest."},{"key":"ref_705","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1172\/JCI123557","article-title":"Chromatin remodeling ATPase BRG1 and PTEN are synthetic lethal in prostate cancer","volume":"129","author":"Ding","year":"2019","journal-title":"J. Clin. Invest."},{"key":"ref_706","doi-asserted-by":"crossref","first-page":"eaau5758","DOI":"10.1126\/scitranslmed.aau5758","article-title":"Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer","volume":"11","author":"Watt","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_707","doi-asserted-by":"crossref","unstructured":"Wadosky, K.M., Wang, Y., Zhang, X., and Goodrich, D.W. (2019). Generation of tumor organoids from genetically engineered mouse models of prostate cancer. J. Vis. Exp., 13.","DOI":"10.3791\/59710"},{"key":"ref_708","doi-asserted-by":"crossref","first-page":"4332","DOI":"10.1158\/1078-0432.CCR-18-0409","article-title":"A PDX\/organoid biobank of advanced prostate cancers captures genomic and phenotypic heterogeneity for disease modeling and therapeutic screening","volume":"24","author":"Beshiri","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_709","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.isci.2019.01.028","article-title":"Prostate stroma increases viability and maintains the branching phenotype of human prostate organoids","volume":"12","author":"Richards","year":"2019","journal-title":"iScience"},{"key":"ref_710","doi-asserted-by":"crossref","unstructured":"Abida, W., Armenia, J., Gopalan, A., Brennan, R., Walsh, M., Barron, D., Danila, D., Rathkopf, D., Morris, M., and Slovin, S. (2017). Prospective genome profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. JCO Precis. Oncol.","DOI":"10.1200\/PO.17.00029"},{"key":"ref_711","doi-asserted-by":"crossref","unstructured":"Chung, J.H., Deawl, N., Sokol, E., Mathew, P., Whitehead, R., Millis, S.Z., Frampton, G.M., Bratslavsky, G., Pal, S.K., and Lee, R.J. (2019). Prospective comprehensive genomic profiling of primary and metastatic prostate tumors. J. Clin. Oncol. Prec. Oncol.","DOI":"10.1200\/PO.18.00283"},{"key":"ref_712","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1038\/s41467-019-09703-y","article-title":"CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation","volume":"10","author":"Krajewska","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_713","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1056\/NEJM200007133430201","article-title":"Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland","volume":"343","author":"Lichtenstein","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_714","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/s41588-018-0142-8","article-title":"Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci","volume":"50","author":"Schumacher","year":"2018","journal-title":"Nat. Genet."},{"key":"ref_715","doi-asserted-by":"crossref","first-page":"djw110","DOI":"10.1093\/jnci\/djw110","article-title":"Family history and probability of prostate cancer, differentiated by risk category: A nationwide population-based study","volume":"108","author":"Bratt","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_716","doi-asserted-by":"crossref","unstructured":"Momozawa, Y., Iwasaki, Y., Hirata, M., Liu, X., Kamatani, Y., Takahashi, A., Sugano, K., Yoshida, T., Murakami, Y., and Matsuda, K. (2019). Germline pathogenic variants in 7636 Japanese patients with prostate cancere and 12,366 controls. J. Natl. Cancer Inst., djz124.","DOI":"10.1093\/jnci\/djz124"},{"key":"ref_717","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/JU.0000000000000137","article-title":"Bringing prostate cancer germline genetics into clinical practice","volume":"202","author":"Das","year":"2019","journal-title":"J. Urol."},{"key":"ref_718","doi-asserted-by":"crossref","unstructured":"Carlo, M.I., Giri, V.N., Paller, C.J., Abida, W., Alumkal, J.J., Beer, T.M., Beltran, H., George, D.J., Heath, E.I., and Higano, C.S. (2018). Evolving intersection between inherited cancer genetics and therapeutic clinical trials in prostate cancer: A white paper from the germline genetics working group of the prostate cancer clinical trilas consortium. JCO Precis. Oncol., 2018.","DOI":"10.1200\/PO.18.00060"},{"key":"ref_719","doi-asserted-by":"crossref","unstructured":"Criscuolo, D., Morra, F., Giannella, R., Cerrato, A., and Celetti, A. (2019). Identification of novel biomarkers of homologous recombination defect in DNA repair to predict sensitivity of prostate cancer cells to PARP-inhibitors. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20123100"},{"key":"ref_720","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","article-title":"State-of-the-art strategies for targeting the DNA damage response in cancer","volume":"16","author":"Tang","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_721","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1158\/2159-8290.CD-12-0120","article-title":"Dual roles of PARP-1 promote cancer growth and progression","volume":"2","author":"Schiewer","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_722","doi-asserted-by":"crossref","first-page":"14573","DOI":"10.1073\/pnas.1908547116","article-title":"Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function","volume":"116","author":"Gui","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_723","first-page":"127613","article-title":"Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage","volume":"130","author":"Chatterjee","year":"2019","journal-title":"J. Clin. Invest."},{"key":"ref_724","doi-asserted-by":"crossref","unstructured":"Torquato, S., Pallavajjala, A., Goldstein, A., Toro, P.V., Silberstein, J.L., Lee, J., Nakazawa, M., Waters, I., CXhu, D., and Shinn, D. (2019). Genetic alterations detected in cell-free DNA are associated with enzalutamide and abiraterone resistance in castration-resistant prostate cancer. JCO Precis. Oncol.","DOI":"10.1200\/PO.18.00227"},{"key":"ref_725","doi-asserted-by":"crossref","unstructured":"Salami, S., Singhal, U., Spratt, D.E., Palapattu, G.S., Hollenbeck, B.K., Schonoft, J.D., Graf, R., Louw, I., Iendrisak, A., and Dugan, L. (2019). Circulating tumor cells as a predictor of treatment response in clinically localized prostate cancer. JCO Precis. Oncol.","DOI":"10.1200\/PO.18.00352"},{"key":"ref_726","doi-asserted-by":"crossref","unstructured":"Baumgart, S.J., Nevedomskaya, E., and Haendler, B. (2019). Dysregulated transcriptional control in prostate cancer. Int. J. Med. Sci., 20.","DOI":"10.3390\/ijms20122883"},{"key":"ref_727","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.molcel.2018.06.036","article-title":"DUB3 promotes BET inhibitor resistance and cancer progression by deubiquitinating BRD4","volume":"761","author":"Jin","year":"2018","journal-title":"Mol. Cell"},{"key":"ref_728","doi-asserted-by":"crossref","unstructured":"Civenni, G., Bosotti, R., Timpanaro, A., Vazquez, R., Merulla, J., Pandit, S., Rossi, S., Albino, D., Allegrini, S., and Mitra, A. (2019). Epigenetic control of mitochondrial fission enables self-renewal of stem-like tumor cells in human prostate cancer. Cell Metab., S1550-4131.","DOI":"10.1016\/j.cmet.2019.05.004"},{"key":"ref_729","doi-asserted-by":"crossref","unstructured":"Shafran, J.S., Andrieu, G.P., Gyorffy, B., and Denis, G.V. (2019). BRD4 regulates metastatic potential of castration-resistant prostate cancer through AHNAK. Mol. Cancer Res., molcanres.1279.2018.","DOI":"10.1158\/1541-7786.MCR-18-1279"},{"key":"ref_730","doi-asserted-by":"crossref","unstructured":"Sharp, A., Welti, J.C., Lambros, M.B.K., Dolling, D., Rodrigues, D.N., Pope, L., Aversa, C., Figueiredo, I., Fraser, J., and Ahmad, Z. (2019). clinical utility of circulating tumour cell androgen receptor splice variant-7 status in metastatic castration-resistant prostate cancer. Eur. Urol., in press.","DOI":"10.1016\/j.eururo.2019.04.006"},{"key":"ref_731","doi-asserted-by":"crossref","unstructured":"Stoykova, G.E., and Schlaepfer, I.R. (2019). Lipid metabolism and endocrine resistance in prostate cancer, and new opportunities for therapy. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20112626"},{"key":"ref_732","doi-asserted-by":"crossref","unstructured":"Frame, F.M., and Maitland, N.J. (2019). Epigenetic control of gene expression in the normal and malignant human prostate: A rapid response which promotes therapeutic resistance. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20102437"},{"key":"ref_733","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s41586-019-1347-4","article-title":"Distinct structural classes of FOXA1 alterations in advancer prostate cancer","volume":"571","author":"Parolia","year":"2019","journal-title":"Nature"},{"key":"ref_734","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/s41586-019-1318-9","article-title":"FOXA1 mutations alter pioneering, differentiation and prostate cancer phenotypes","volume":"571","author":"Adams","year":"2019","journal-title":"Nature"}],"container-title":["Medicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2305-6320\/6\/3\/82\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:11:18Z","timestamp":1760188278000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2305-6320\/6\/3\/82"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,30]]},"references-count":734,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,9]]}},"alternative-id":["medicines6030082"],"URL":"https:\/\/doi.org\/10.3390\/medicines6030082","relation":{},"ISSN":["2305-6320"],"issn-type":[{"value":"2305-6320","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,30]]}}}